

Weekly

September 18, 2009 / Vol. 58 / No. 36

Nonfatal Scald-Related Burns Among Adults Aged ≥65 Years – United States, 2001–2006

Scalds, which are burns attributed to hot liquids or steam, account for 33%-58% of all patients hospitalized for burns in the United States (1–3). Adults aged ≥ 65 years have a worse prognosis than younger patients after scald burns because of age-related factors and comorbid medical conditions (4), and they are subject to more extensive medical treatment than younger adults. To estimate the number of emergency department (ED) visits for nonfatal scald burns among U.S. adults aged \geq 65 years and describe their characteristics, CDC analyzed ED visit data from the National Electronic Injury Surveillance System All Injury Program (NEISS-AIP) for 2001–2006. This report summarizes the results, which indicated that adults aged ≥65 years made an estimated 51,700 initial visits to EDs for nonfatal scald burns during 2001–2006, for an average of 8,620 visits per year and an estimated average annual rate of 23.8 visits per 100,000 population. Two thirds of visits were made by women. Most (76%) of the nonfatal scald injuries occurred at home; 42% were associated with hot food and 30% with hot water or steam. The findings in this report highlight the need for effective scald-prevention programs targeted to older persons.

NEISS–AIP, maintained by the Consumer Product Safety Commission (CPSC), collects data on initial ED visits for all types and causes of injuries. The system uses a nationally representative sample of hospitals from 66 of the 100 NEISS–AIP hospitals that have 24-hour EDs in the United States (5). Data are collected from the medical records of new ED admissions, and only the most severe injury is recorded for each visit. Data include up to two product codes and a two-line narrative describing the circumstances of the injury (5).

For this analysis, a visit for nonfatal scald burn was defined as a visit by a patient aged ≥ 65 years to a hospital ED for scald burns at any time during the study period, 2001–2006. Visits were included if they met all three of the following conditions: 1) the principal diagnosis was "scald," "scald burn," "scald related," or "burn due to hot liquid or steam," or the narrative describing burn circumstance contained a common product involving hot liquid or steam (e.g., pressure cooker, microwave, or bathtub), 2) the ED visit was the first visit for treatment of this scald burn, and 3) the scald-burn incident was not work related. Visits were excluded if the burn involved only smoke, fire, chemical, electrical, radiation, or flash burns. Patients who were dead on arrival or died shortly thereafter were excluded.

All ED narratives associated with nonfatal scald burns were reviewed. NEISS–AIP provides space for coding two products associated with the injury. For visits with two product codes, the code deemed to be more descriptive of the circumstances of the injury was retained in the analysis to create a mutually

INSIDE

- 997 National, State, and Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2008
- 1002 Update on Vaccine-Derived Polioviruses Worldwide, January 2008–June 2009
- 1006 Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Hepatitis A Vaccine in Close Contacts of Newly Arriving International Adoptees
- 1008 Licensure of a *Haemophilus influenzae* Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine
- 1009 Update: Influenza Activity United States, April-August 2009
- 1013 QuickStats

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2009;58:[inclusive page numbers].

Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH Director Tanja Popovic, MD, PhD Chief Science Officer James W. Stephens, PhD Associate Director for Science Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Katherine L. Daniel, PhD Deputy Director, National Center for Health Marketing

Editorial and Production Staff

Frederic E. Shaw, MD, JD Editor, MMWR Series Christine G. Casey, MD Deputy Editor, MMWR Series Robert A. Gunn, MD, MPH Associate Editor, MMWR Series Teresa F. Rutledge Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Donald G. Meadows, MA Jude C. Rutledge Writers-Editors Martha F. Boyd Lead Visual Information Specialist Malbea A. LaPete Stephen R. Spriggs Terraye M. Starr Visual Information Specialists Kim L. Bright Quang M. Doan, MBA Phyllis H. King Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR William Schaffner, MD, Nashville, TN Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

exclusive set of product categories.* If multiple body parts were injured, only the most serious injury was used to create a set of mutually exclusive categories for analysis.

Visit estimates were based on weighted data from patients aged ≥ 65 years who were treated for nonfatal scald burns at EDs that reported data to NEISS-AIP. For each scald-related visit, NEISS–AIP assigns a sample weight based on its inverse probability of selection; these weights are summed to provide national estimates of nonfatal scald-related burns. Rates per 100,000 persons were calculated using U.S. Census Bureau population estimates (6). Subgroup estimates with <20 visits or with a coefficient of variation >30% were considered unstable and were not reported. A direct variance estimation procedure that accounts for the sample weights and complex sample design was used to calculate 95% confidence intervals.

A total of 705 ED visits for nonfatal scald burns were identified during the study period. No consistent temporal variation in the number of visits was observed across the 6 years,[†] or by hours of the day, days of the week, or seasons of the year. In 536 (76%) of the 705 visits, the nonfatal scald burn occurred at home, most commonly in the kitchen (60%), dining area (20%), and bathroom (11%). Hot food was involved in 42% of burns (rate = 9.9 per 100,000), hot water or steam in 30% (rate = 7.2), and contact with cookware in 9% (rate = 2.2); 8% (rate = 1.9) of nonfatal scald burns were related to home or kitchen appliances, including 3% with microwave ovens. Among the 705 visit narratives, 90% recorded the type of liquids associated with the burn, including hot (boiling) water (42%), hot oil (21%), coffee (15%), food (12%), steam (7%), and tea (3%).

Scald burn visits were more common among females (rate = 27.2) than males (rate = 19.0). The most commonly affected body parts were upper extremities (arm/hand) (42%) and lower extremities (leg/foot) (38%), followed by head/neck (8%) and lower trunk (7%). Overall, 93% of ED visits resulted in discharge after treatment; 4.2% of the patients were hospitalized, and 2% of the patients were transferred to other hospitals for more specialized care.

During 2001–2006, an estimated 139,770 initial ED visits by persons aged \geq 65 years occurred for nonfatal fire or burn injuries, of which 53,600 (38%) were nonfatal scald burns. After excluding work-related scald burns, the remaining 51,700 visits for nonfatal scald-related burns yielded a

^{*} If one of the two codes listed food, the other product code was recorded. For example, if the two codes referred to a microwave and food, microwave was recorded. If one of the two codes was water or steam, the other product code was recorded; water/steam was only assigned when no other information was available, because all scald burns involve a heated liquid or steam. For visits with two nonwater or nonfood product codes, the narratives were reviewed to choose which product was most descriptive of the injury circumstances.

[†] Number of visits by year: 2001 (110), 2002 (142), 2003 (92), 2004 (123), 2005 (122), and 2006 (116).

national estimated annual incidence of 23.8 per 100,000 persons (Table 1). During the 6-year period, the estimated average annual number of initial ED visits for nonfatal scald-related burns in persons aged \geq 65 years was 8,620. The highest estimated annual numbers of ED visits were for scald burns to the arm/hand and leg/foot, and the highest number of ED visits were for scald burns caused by food or water/steam (Table 2).

Reported by: D Hungerford, DrPH, E Sullivent, MD, K Thomas, MPH, M Wald, MPH, Div of Injury Response, National Center for Injury Prevention and Control; M Galle, MD, EIS Officer, CDC.

Editorial Note: This report provides the first national estimate of ED visits for nonfatal scald burns in older adults. Compared with younger adults, older adults with scald-related burns are more frequently admitted to hospitals, experience longer intensive-care unit and hospital stays, have increased hospital mortality, and are transferred more frequently to rehabilitation and long-term nursing facilities (3,4). The results of the analysis in this report indicate that, during 2001–2006, older adults made a substantial number of visits to U.S. EDs annually for scald burns. The burns resulted mainly in injuries to the arm/hand and leg/foot, were caused mostly by hot food and hot water or steam, and occurred predominantly in the kitchen, dining area, or bathroom. Greater awareness of the risk for these injuries and the use of simple precautions might help reduce these injuries (7,8) (Box).

The closest parallel analysis to the one reported here is the National Burn Registry (NBR) (2). However, NBR collects data on inpatients from burn centers rather than from ED

TABLE 1. Average annual estimates and rates* of emergency department visits for nonfatal scald burns, adults aged ≥65 years, by age group, sex, and disposition — National Electronic Injury Surveillance System (NEISS) All Injury Program, 2001–2006

Characteristic	No.	(%)	Rate	(95% CI†)
Total	8,620	(100)	23.8	(20.0–27.6)
Age group (yrs)				
65–79 ≥80	6,460 2,160	(75) (25)	24.9 21.0	(21.0–28.8) (15.6–26.3)
Sex				
Male Female	2,870 5,740	(33) (67)	19.0 27.2	(14.8–23.3) (22.8–31.6)
Disposition				
Treated, released Hospitalized/transferred Other [§]	7,970 510 130	(93) (6) (2)	22.0 1.4 0.4	(18.6–25.4) (1.0–1.9) (0.0–0.7)

* Per 100,000 population, based on 2000 U.S. Census. Estimates might not sum to totals because of rounding.

[†]Confidence interval.

[§] Patients left against medical advice or left without being seen by attending physician. Estimate are unstable because the coefficient of variation is >30%. TABLE 2. Annual estimates and percentages* of emergency department visits for nonfatal scald burns, adults aged ≥65 years, by affected body part and associated product — National Electronic Injury Surveillance System (NEISS) All Injury Program, 2001–2006

Burn site and source	No.	(%)	(95% Cl [†])
Total	8,620	(100)	(7,240–9,993)
Body part [§]			
Head/neck	680	(8)	(426-941)
Upper trunk	370	(4)	(174–561)
Lower trunk	580	(7)	(357-792)
Arm/hand	3,580	(42)	(3,011–4,140)
Leg/foot	3,310	(38)	(2,770-3,846)
Other [¶]	90	(1)	(6–153)
Unknown [¶]	20	(0)	(-22–67)
Associated product			
Food	3,580	(42)	(2,867-4,298)
Water/steam	2,600	(30)	(1,954-3,243)
Cookware**	780	(9)	(518-1,043)
Home/kitchen appliances ^{††}	690	(8)	(481–901)
Bathroom products§§	220	(3)	(92-356)
Dining accessories ^{¶¶}	220	(3)	(92–345)
Other***	480	(6)	(275–675)
Unknown [¶]	50	(1)	(-9–102)

* Estimates might not sum to totals because of rounding.

[†] Confidence interval.

§ If multiple bodty parts were injured, only the most serious injury was recorded. Categories are mutually exclusive.

I Estimates are unstable because the coefficient of variation of the estimate is >30%.

** Includes metal cookware and pressure cookers.

^{††} Includes microwave, oven, range, and heaters.

§§ Includes bathtub, shower, and whirlpool.

^{¶¶} Includes tableware and candles.

*** Includes products and product categories (e.g., personal care items) for which estimates were unstable.

visits to general hospitals, the source for NEISS–AIP data. The NBR results corroborate the findings of this report: the leading causes of nonfatal scald burns were contact with hot food, liquids, and steam. The NBR results also indicate that nonfatal scald burns occurred mainly in the kitchen, dining area, and bathroom. NBR data show that 14% of patients hospitalized with all types of burns were aged ≥60 years, and approximately 35% of these patients sustained nonfatal scald burns from hot liquids, steam, or boiling tap water. Notably, the National Fire Protection Association determined that 41% of all scald burns from cooking equipment in 2006 were caused by microwave ovens (9).

The findings in this report are subject to at least four limitations. First, the report underestimates the prevalence of nonfatal scald burns because it does not include patients treated outside of hospital EDs (e.g., outpatient clinics, private doctor's offices, and emergency walk-in clinics). Second, the report might underestimate the number of scald burns in patients with multiple injuries because the system records only one injury diagnosis. Third, narrative descriptions from medical records did not always provide details or consistent information on circumstances, products involved, injury severity, or mechanism of nonfatal scald burns. Finally, the number of ED visits in certain subgroups was small and did not support stable national estimates.

This report provides a baseline national estimate that can be used for comparison in future studies. The rapid growth in the U.S. population of older persons (10) makes monitoring of these injuries especially important. To reduce scald burns among older persons, further development of education and prevention strategies is needed, and these strategies should be evaluated for effectiveness.

Acknowledgments

The findings in this report are based, in part, on contributions from T Schroeder, MS, C Irish, MS, and other staff members of the Div of Hazard and Injury Data Systems, Consumer Product Safety Commission; J Annest, PhD, and T Haileysus, MS, Office of Statistics and Programming, and M Ballesteros, PhD, Div of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC.

References

- 1. CDC. Web-based Injury Statistics Query and Reporting System (WISQARS). Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control; 2009. Available at http://www.cdc.gov/injury/wisqars/index.html.
- American Burn Association. National Burn Repository, 2005 report. Chicago, IL: American Burn Association; 2006. Available at http:// www.ameriburn.org/NBR2005.pdf.
- 3. Ehrlich AR, Kathpalia S, Boyarsky Y, Schechter A, Bijur P. Elderly patients discharged home from the emergency department with minor burns. Burns 2005;31:717–20.
- Alden NE, Bessey PQ, Rabbitts A, Hyden PJ, Yurt RW. Tap water scalds among seniors and the elderly: socio-economics and implications for prevention. Burns 2007;33:666–9.
- 5. US Consumer Product Safety Commission. NEISS All Injury Program: sample design and implementation. Washington, DC: US Consumer Product Safety Commission; 2001.
- 6. CDC. Vintage 2005 bridged-race postcensal population estimates. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2006. Available at http://www. cdc.gov/nchs/nvss/bridged_race.htm.
- American Burn Association. Scalds: a burning issue: a campaign kit for Burn Awareness Week 2000. Chicago, IL: American Burn Association; 2000. Available at http://www.ameriburn.org/Preven/2000Prevention/ Scald2000PrevetionKit.pdf.
- US Fire Administration, National Fire Protection Association. Other cooking, food, and hot beverage burns [Chapter 8]. In: Behavioral mitigation of cooking fires through strategies based on statistical analysis. Emmitsburg, MD: US Department of Homeland Security, US Fire Administration; 2007:55–8. Available at http://www.usfa.dhs.gov/ downloads/pdf/publications/cooking/fa-312.pdf.
- 9. Hall JR, Jr. Home fires involving cooking equipment. Quincy, MA: National Fire Protection Association; 2008. Available at http://www. nfpa.org/assets/files/PDF/Microwavefactsheet.pdf.
- Day JC. Population projections of the United States, by age, sex, race, and Hispanic origin: 1993 to 2050. Current Population Reports, P25-1104. Washington, DC: US Department of Commerce, Bureau of the Census; 1993.

BOX. Suggested measures to reduce residential scald-related burns in older persons living independently at home*

Kitchen

- Plan ahead before cooking. Wear short- or tight-sleeved garments while cooking. Always ask for assistance if physically challenged.
- Plug ovens and other cooking appliances directly into an outlet. Never use an extension cord for a cooking appliance; it can trip the user, which can cause hot food spills. Keep all appliance cords coiled and away from counter edges.
- When deep frying, prevent contact of water and steam with hot oil; allow hot oil to cool before removal.
- To prevent spills, turn pot handles away from the stove's edge and use the back burner when possible.
- Only use dry oven mitts or potholders when moving hot food from ovens, microwave ovens, or stovetops.
- During meals, place hot items in the center of the table; use nonslip placemats instead of tablecloths.
- Treat a burn right away by putting it in cool water. Cool the burn for 3–5 minutes and immediately seek medical attention.

Use Microwave Ovens Safely

- Place the microwave oven at a safe height, within easy reach of all users, and lower than the face of the person using the microwave.
- Heat foods only in containers or dishes that are safe for microwave use. Never microwave uncracked eggs.
- To prevent steam build-up, remove tight lids on food containers, puncture plastic wraps, or use vented containers.
- Open heated food containers slowly, away from face or hands, to avoid steam scalds. Let cooked food stand for 1–2 minutes before removing from microwave oven.
- Foods heat unevenly in microwave ovens; stir and test before eating.

Bathrooms and Sinks

- Adjust thermostat on water heater to keep hot water <120°F. Install antiscald tempering valves or thermostatic mixing valves.
- Before using, check water temperature with a kitchen thermometer or test with your elbow, wrist, or hand with spread fingers.
- Start to fill bathtub with cold water and slowly mix with hot water. Avoid running water in other rooms during this time (it might increase the temperature of the water filling the bathtub) and turn off the hot water first.

^{*}Adapted from recommendations of the American Burn Association and the National Fire Protection Association.

National, State, and Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years – United States, 2008

In recent years, the Advisory Committee on Immunization Practices (ACIP) has recommended three newly licensed vaccines: meningococcal conjugate vaccine (MCV4; 1 dose); tetanus, diphtheria, acellular pertussis vaccine (Tdap; 1 dose); and (for girls) quadrivalent human papillomavirus vaccine (HPV4; 3 doses) (1). ACIP also recommends that adolescents receive recommended vaccinations that were missed during childhood: measles, mumps, rubella vaccine (MMR; 2 doses); hepatitis B vaccine (HepB; 3 doses); and varicella vaccine (VAR; 2 doses) (1). Since 2006, CDC has conducted the National Immunization Survey-Teen (NIS-Teen) to estimate vaccination coverage from a national sample of adolescents aged 13-17 years (2). This report summarizes results from the 2008 NIS-Teen and, for the first time, includes estimates for each of the 50 states and selected local areas. Nationally, vaccination coverage for the three most recently recommended adolescent vaccinations and one childhood vaccination increased from 2007 to 2008: MCV4 (from 32.4% to 41.8%), Tdap (from 30.4% to 40.8%), ≥1 dose of HPV4 (from 25.1% to 37.2%), and ≥ 2 doses of VAR among those without disease history (from 18.8% to 34.1%). However, substantial variability in vaccination coverage was observed in 2008 among state and local areas and by race/ethnicity and poverty status. For the first time, the Healthy People 2010 target of 90% coverage among adolescents aged 13–15 years was met for MMR and HepB. Public health agencies should continue annual monitoring of adolescent vaccination coverage levels to identify trends and differences by geographic area, race/ ethnicity, and poverty status.

NIS-Teen collects vaccination information on adolescents aged 13–17 years* in the 50 states and selected local areas[†] using a random-digit–dialed sample of household telephone numbers. After parents/guardians grant permission, surveys are mailed to all of the adolescents' vaccination providers identified by the parents/guardians to obtain vaccination histories (2). During 2008, NIS-Teen was expanded; the survey was administered over four quarters compared with only the fourth quarter in 2006 and 2007 (2,3), and the analytic sample size increased nearly fivefold from 2006 and 2007 (2,3). For

2008 NIS-Teen, the household response rate[§] was 58.7%; a total of 17,835 adolescents with provider-verified vaccination records were included in this report. A description of NIS-Teen methods and survey content has been published (2). Statistical differences in vaccination coverage were evaluated using chi square and t-tests and were considered statistically significant at p<0.05.

Among adolescents aged 13–17 years, vaccination coverage with ≥ 1 dose of tetanus, diphtheria toxoid vaccine (Td) or Tdap after age 10 years remained stable at 72.2%; however, coverage with ≥ 1 dose of Tdap increased from 30.4% in 2007 to 40.8% in 2008 (Table 1). Vaccination coverage with ≥ 1 dose of MCV4 increased from 32.4% in 2007 to 41.8% in 2008. For HPV4, 37.2% of adolescent females had initiated the vaccination series (≥ 1 dose) in 2008, compared with 25.1% in 2007, and 17.9% of females had received ≥ 3 doses. Among adolescent females who initiated the HPV4 series, 79.4% had received their first dose at least 24 weeks before the interview date (the minimum period in which to complete the series) (4); of these, 59.6% (95% confidence interval [CI] = 55.5–63.5) had received ≥ 3 doses.

Vaccination coverage with ≥ 2 doses of MMR and ≥ 3 doses of HepB remained steady compared with 2007 (Table 1). Fewer adolescents had a reported history of varicella disease in 2008 (59.8%) compared with 2007 (65.8%), and more adolescents had received ≥ 1 dose and ≥ 2 doses of VAR (Table 1).

Substantial differences were observed in vaccination coverage estimates among states and local areas (Table 2). Three states (Arizona, New Hampshire, and New York) had coverage of >50% for all three vaccines routinely recommended for adolescents (Tdap, MCV4, and HPV4). Other states with coverage >50% for at least one of the three vaccines, including Colorado, New Mexico, Pennsylvania, and Wisconsin (≥1 dose of Tdap); Delaware, District of Columbia, Louisiana, Maryland, Massachusetts, New Jersey, Pennsylvania, Rhode Island, and Wisconsin (≥1 dose of MCV4); and Massachusetts, Rhode Island, and Vermont (≥1 dose of HPV4).

Variability in coverage was observed among racial/ethnic[¶] groups and by poverty status^{**} (Table 3). Blacks (87.9%) had lower vaccination coverage percentages than whites (93.7%) for

^{*} Eligible participants were born during January 1990–February 1996.

[†] Six local areas that received federal immunization grants were sampled separately: District of Columbia; Chicago, Illinois; New York, New York; Philadelphia County, Pennsylvania; Bexar County, Texas; and Houston, Texas.

[§] The Council of American Survey Research Organizations (CASRO) household response rate is the product of the resolution rate (82.2%), screening completion rate (83.8%), and interview completion rate (85.2%).

⁹ Respondents who self-identified as white, black, Asian, or American Indian/ Alaska Native were all considered non-Hispanic. Persons who self-identified as Hispanic might be of any race.

^{**} Adolescents were classified as below poverty level if their total family income was less than the federal poverty level specified for the applicable family size and number of children aged <18 years. All others were classified as at or above the poverty level. Additional information is available at http://www.census.gov/ hhes/www/poverty.html. Poverty status was unknown for 744 adolescents.

TABLE 1. Estimated vaccination coverage among adolescents aged 13–17 years,* by age at interview and selected vaccines and doses — National Immunization Survey-Teen, United States, 2008

					A	ge (yrs)						Over	all	
	(n	13 = 3,455)	(n :	14 (n = 3,641)		15 (n = 3,666)		16 = 3,731)	17 (n = 3,342)		2008 (n = 17,835)		(n	2007 i = 2,947)
Vaccines and doses	%	(95% CI†)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
MMR [§] ≥2 doses	90.3	(88.0–92.2)	91.8	(89.8–93.4)	90.1	(88.1–91.8)	86.2	(83.6-88.4)	88.1	(86.1–89.9)	89.3	(88.4–90.2)	88.9	(87.3–90.4)
Hepatitis B ≥3 doses	92.8	(91.2–94.1)	93.1	(91.5–94.3)	89.6	(87.0–91.7)	81.5	(78.6–84.1)	82.9	(80.7–84.8)	87.9	(86.9–88.8)	87.6	(86.0–89.0)
Varicella History of varicella disease ¹¹ Among adolescents without history of disease:	42.3	(39.2–45.5)	50.1	(47.1–53.1)	62.8	(59.5–66.0)	68.2	(65.1–71.2)	74.8	(71.3–78.1)	59.8	(58.4–61.3)**	65.8	(63.5–68.0)
≥1 dose	89.6	(87.1–91.6)	85.2	(81.6–88.2)	80.2	(75.2–84.4)	76.5	(71.8–80.6)	68.2	(61.7–74.1)	81.9	(80.2–83.5)**	75.7	(72.2-79.0)
≥2 doses History of disease or received ≥1 dose varicella vaccine		(36.4–44.9) (92.5–95.2)		(29.9–39.3) (90.7–94.2)		(29.1–39.7) (90.5–94.3)		(22.9–34.0) (91.0–93.8)		(18.9–36.8) (90.5–93.3)		(31.8–36.6)** (92.0–93.4)	18.8 91.7	```
Td or Tdap since age 10 years ^{††} ≥1 dose Td or Tdap ≥1 dose Tdap	64.1 51.9	(61.0–67.2) (48.7–55.1)		(66.5–72.7) (44.0–50.6)		(75.2–80.0) (38.2–44.9)		(71.9–77.5) (32.1–38.1)		(70.7–76.6) (25.5–32.1)		(70.8–73.4) (39.3–42.3)**	72.3 30.4	· /
MCV4 ≤1 dose ^{§§}	42.0	(38.8–45.1)	43.0	(39.8–46.4)	46.4	(43.0–49.7)	40.5	(37.4–43.6)	36.7	(33.5–40.0)	41.8	(40.3–43.2)**	32.4	(30.2–34.7)
HPV4 ¹¹¹														
≥1 dose ≥3 doses	35.2 14.5	(31.1–39.6) (11.9–17.5)		(29.6–38.2) (13.6–20.2)		(/		(31.7–39.9) (15.6–22.4)		(33.3–43.9) (16.3–26.3)		(35.2–39.3)** (16.3–19.6)	25.1	(22.3-28.1)

* Adolescents (N = 17,835) in 2008 NIS-Teen were born during January 1990-February 1996.

t Confidence interval.

§ Measles, mumps, and rubella vaccine.

[¶] By parent/guardian report or provider records.

** Significant difference compared with NIS-Teen 2007 overall estimates (p<0.05).

⁺⁺ Includes percentages receiving tetanus and diphtheria toxoids vaccine (Td), fetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), or tetanus-unknown type vaccine.

§§ Includes percentages receiving meningococcal conjugate vaccine (MCV4) or meningococcal-unknown type vaccine.

11 Quadrivalent human papillomavirus vaccine. Percentages reported among females only (n = 8,607); HPV4 vaccine is not recommended for males.
*** Estimate not reported because unweighted sample size for the denominator was <30.</p>

TABLE 2. Estimated vaccination coverage among adolescents aged 13-17 years,* by state and selected areas and selected vaccines and doses — National Immunization Survey-Teen, United States, 2008

	Vac			y recommend nt catch-up v		ring childhood s)	Vaccine doses routinely recommended for add						lolesc	ents
		≥2 MMR†	2	≥3 HepB§	2	≥1 VAR [¶]	≥1	Td or Tdap**		≥1 Tdap	≥	1 MCV4 ⁺⁺	2	1 HPV4§§
State/Area	%	(95% CI¶¶)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
United States	89.3	(88.4–90.2)	87.9	(86.9–88.8)	81.9	(80.2–83.5)	72.2	(70.8–73.4)	40.8	(39.3–42.3)	41.8	(40.3–43.2)	37.2	(35.2–39.3)
Alabama	89.8	(85.7–92.8)	68.2	(62.3–73.5)	71.2	(61.6–79.2)	70.1	(64.6–75.1)	44.0	(38.3–49.8)	29.9	(24.8–35.5)	32.8	(25.5–41.1)
Alaska	84.4	(79.3–88.5)	86.9	(82.3–90.5)	66.7	(55.4–76.4)***	68.3	(62.2–73.7)	42.1	(36.2–48.3)	30.5	(25.1–36.5)	38.8	(30.6–47.8)
Arizona	82.4	(75.7–87.6)	83.9	(77.9–88.5)	85.4	(74.1–92.3)	74.0	(66.5–80.3)	53.8	(46.4–61.0)	51.5	(44.2–58.7)	50.5	(40.3–60.7)***
Arkansas	90.2	(86.3–93.1)	90.9	(87.1–93.7)	84.9	(77.5–90.1)	46.1	(40.4–52.0)	23.8	(19.2–29.1)	14.5	(10.8–19.1)	22.4	(16.2–30.2)
California	91.9	(86.9–95.1)	89.9	(83.8–93.8)	92.9	(87.4–96.1)	71.3	(64.1–77.5)	43.7	(36.3–51.4)	48.0	(40.5–55.6)	46.6	(36.3–57.3)***
Colorado	91.0	(86.8–94.0)	94.6	(91.0–96.8)	85.3	(77.3–90.8)	77.4	(70.8–82.9)	63.0	(55.9–69.5)	32.4	(26.3–39.2)	33.5	(25.5–42.6)
Connecticut	95.7	(91.5–97.9)	98.4	(94.8–99.5)	97.6	(91.6–99.4)	79.8	(73.2–85.0)	45.4	(38.5–52.5)	45.2	(38.2–52.4)	45.0	(35.6–54.8)
Delaware	94.8	(90.4–97.3)	95.2	(91.9–97.2)	86.1	(78.7–91.2)	78.6	(72.9–83.3)	43.1	(36.9–49.6)	58.6	(52.1–64.7)	46.8	(37.9–56.0)
District of Columbia	94.6	(89.9–97.2)	94.8	(90.7–97.2)	96.4	(92.1–98.4)	84.7	(79.9–88.6)	32.7	(27.1–38.9)	58.1	(51.7–64.2)	38.7	(30.0–48.3)
Florida	92.3	(85.8–96.0)	92.8	(87.6–96.0)	80.0	(66.1-89.1)***	79.4	(70.3-86.2)	29.0	(22.6–36.2)	33.6	(26.7–41.2)	36.7	(26.7-48.0)***
Georgia	92.8	(87.4–96.0)	91.6	(87.4–94.5)	91.4	(83.2–95.8)	70.9	(64.6–76.4)	37.8	(31.6–44.4)	41.6	(35.2–48.3)	18.5	(13.0–25.5)
Hawaii	91.4	(86.9–94.4)	93.1	(88.9–95.8)	89.7	(82.4–94.3)	71.6	(65.7–76.9)	32.0	(26.5–38.0)	44.1	(38.1–50.3)	40.2	(32.3–48.6)
Idaho	73.2	(66.4–79.0)	73.1	(66.4–78.8)	61.1	(47.3–73.3)***	51.3	(44.5–58.0)	31.7	(25.7–38.3)	29.9	(24.1–36.5)	28.4	(20.5–38.0)
Illinois	89.5	(85.1–92.7)	93.2	(89.5–95.7)	74.2	(65.0–81.6)	72.9	(67.7–77.6)	45.4	(39.9–51.0)	41.9	(36.5–47.6)	27.0	(20.8–34.3)
Chicago	83.4	(78.3–87.5)	90.2	(85.5–93.5)	79.3	(70.8-85.8)	71.8	(65.6–77.3)	44.2	(38.0–50.5)	41.1	(35.1–47.5)	28.6	(20.8–37.9)
Rest of state	91.1	(84.8–95.0)	94.0	(88.6–96.9)	73.0	(60.2-82.8)***	73.5	(66.4–79.5)	45.5	(38.4–52.9)	42.8	(35.7–50.2)	25.7	(18.0–35.3)
Indiana	91.7	(88.2–94.1)	86.2	(81.4–90.0)	70.4	(59.9–79.1)	53.6	(47.4–59.7)	31.2	(26.1–36.7)	31.8	(26.5–37.8)	26.1	(19.8–33.6)
Iowa	86.4	(81.7–90.1)	79.2	(73.9–83.6)	68.4	(56.4–78.4)***	65.9	(59.4–71.8)	43.5	(37.4–49.9)	31.9	(26.4–38.0)	41.9	(32.6–51.9)
Kansas	84.1	(78.3–88.6)	71.4	(64.6–77.4)	62.5	(49.5–73.9)***	69.9	(63.4–75.6)	46.8	(40.1–53.7)	25.6	(20.0–32.3)	30.1	(21.7–40.0)
Kentucky	96.2	(93.2–97.9)	93.3	(89.3–95.9)	74.7	(63.9-83.1)	82.0	(76.2-86.6)	28.1	(22.6–34.3)	30.9	(25.3–37.0)	26.3	(18.8–35.4)
Louisiana	89.0	(84.8–92.2)	85.1	(80.3–88.9)	68.9	(57.3–78.6)***	74.9	(69.3–79.8)	35.3	(29.8–41.3)	53.6	(47.5–59.6)	36.6	28.3-45.6
Maine	92.6	(88.9–95.2)	81.4	(76.0–85.7)	89.7	(81.5–94.5)	75.0	(69.1–80.1)	43.0	(36.9–49.3)	35.6	(29.9–41.7)	40.3	(32.2–49.0)
Maryland	92.3	(88.1–95.1)	91.2	(87.1–94.1)	86.7	(78.4–92.1)	79.0	(73.0–83.9)	37.9	(32.2–44.0)	54.6	(48.2–60.7)	41.1	(32.4–50.5)
Massachusetts	99.5	(98.2–99.8)	97.4	(95.0–98.6)	95.0	(85.1–98.4)	94.4	(90.5–96.8)	43.3	(37.2–49.7)	55.9	(49.4–62.2)	53.3	(43.8–62.6)
Michigan	94.6	(91.4–96.7)	92.8	(89.3–95.2)	86.8	(77.5–92.6)	69.9	(63.9–75.3)	33.6	(27.9–39.8)	39.9	(33.8–46.2)	32.3	(23.8–42.1)

MMWR

TABLE 2. (Continued) Estimated vaccination coverage among adolescents aged 13–17 years,* by state and selected areas and
selected vaccines and doses — National Immunization Survey–Teen, United States, 2008

≥2 MMR [†] (95% Cl ^{¶¶}) (85.5–93.4) (91.6–96.5) 2 (79.0–88.4) (78.6–88.3) 6 (83.7–92.0) 6 (83.5–92.6)	89.7 60.8 87.0 75.2 90.6	3 HepB[§] (95% Cl) (85.4–92.9) (55.0–66.2) (82.4–90.5)	% 84.8 40.0	1 VAR¹ (95% Cl) (76.2–90.6)	≥1 ⁻ %	۲d or Tdap**		≥1 Tdap	≥	1 MCV4 ⁺⁺	;	≥1 HPV4 ^{§§}
(85.5–93.4) (91.6–96.5) (79.0–88.4) (78.6–88.3) (83.7–92.0) (83.5–92.6)	89.7 60.8 87.0 75.2	(85.4–92.9) (55.0–66.2)	84.8	()	%						-	
(91.6–96.5) (79.0–88.4) (78.6–88.3) (83.7–92.0) (83.5–92.6)	60.8 87.0 75.2	(55.0–66.2)		(76.0.00.6)		(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
2 (79.0–88.4) (78.6–88.3) (83.7–92.0) 8 (83.5–92.6)	87.0 75.2	()	40.0	(70.2-90.0)	88.7	(84.2–92.0)	40.7	(34.8–46.8)	38.9	(33.1–45.1)	33.6	(26.4-41.7)
(78.6–88.3) (83.7–92.0) (83.5–92.6)	75.2	(82.4-90.5)	40.0	(31.0-49.8)	28.7	(23.7–34.3)	19.6	(15.3–24.7)	14.8	(10.9–19.8)	15.8	(10.6–23.0)
6 (83.7–92.0) 6 (83.5–92.6)			62.7	(51.6-72.6)***	67.9	(62.0-73.3)	44.1	(38.1–50.2)	35.3	(29.9-41.2)	31.6	(23.9-40.6)
(83.5–92.6)	90.6	(69.4-80.1)	70.1	(58.4-79.7)***	69.1	(62.6-74.8)	44.2	(37.8–50.7)	17.8	(13.1–23.6)		
()		(86.1–93.8)	86.1	(78.3–91.4)	71.5	(65.6-76.7)	42.2	(36.5-48.0)	37.2	(31.8-42.9)	29.5	(23.0-37.0)
	82.7	(76.6-87.4)	64.8	(53.0-75.0)***	69.0	(61.6-75.5)	45.9	(38.6-53.2)	29.6	(23.3-36.9)	30.0	(21.2-40.4)
(90.0-97.5)	92.7	(88.2–95.5)	93.2	(85.7–96.9)	84.2	(77.1-89.4)	53.1	(45.8–60.2)	54.6	(47.3–61.7)	54.4	(44.3-64.1)
(87.6-94.6)	94.5	(91.0–96.7)	86.2	(78.9–91.2)	78.1	(72.4-83.0)	43.0	(36.9-49.3)	60.6	(54.3-66.6)	43.0	(34.3–52.1)
(78.2-88.7)	83.1	(76.5-88.1)	69.0	(58.7–77.8)	75.1	(68.8–80.6)	50.4	(43.7–57.0)	39.6	(33.3–46.3)	48.3	(38.4-58.4)***
(89.7–94.8)	93.0	(89.7–95.3)	88.7	(83.0–92.6)	85.5	(81.9-88.5)	53.8	(48.9–58.6)	56.0	(51.1–60.8)	50.2	(43.1–57.3)
(84.0–93.5)	90.9	(86.0–94.1)	85.7	(75.1–92.3)	85.4	(80.0-89.5)	49.4	(42.3–56.5)	53.5	(46.4–60.5)	48.3	(38.0-58.7)***
(91.2–96.8)	94.5	(89.3–97.3)	90.9	(84.1–95.0)	85.6	(80.6–89.5)	56.8	(50.1–63.2)	57.7	(51.1–64.0)	51.5	(41.9–61.0)
(76.4-86.8)	81.4	(75.2-86.4)	57.7	(47.1–67.7)***	63.6	(56.9–69.8)	28.0	(22.8–33.8)	30.7	(25.2–36.9)	34.4	(26.3-43.6)
(90.4–96.0)	87.9	(83.4–91.3)	76.1	(66.1-83.8)	75.0	(69.4–79.9)	47.8	(42.2–53.5)	47.4	(41.7–53.1)	28.7	(21.9-36.7)
(79.7–88.8)	76.9	(71.0-81.9)	77.4	(65.9–85.9)***	57.8	(51.3–64.1)	30.6	(25.2–36.7)	37.7	(31.7–44.0)	29.1	(21.6–37.9)
(85.9–93.3)	88.9	(84.0–92.4)	83.1	(73.6–89.6)	59.5	(53.1–65.5)	28.6	(23.3–34.5)	25.1	(20.0–30.9)	35.5	(27.3–44.7)
(82.3–91.6)	88.0	(81.5–92.4)	89.0	(79.6–94.3)	64.1	(56.6–71.0)	38.9	(32.2-45.9)	29.6	(23.7–36.3)		(25.6-45.3)
(91.5-96.6)	95.3	(91.8–97.3)	94.2	(89.7–96.8)	82.0	(77.1–86.0)	51.2	(45.8–56.6)	59.7	(54.2-65.1)	46.1	(38.7–53.7)
(84.7–92.6)	93.3	(89.4–95.8)	91.8	(85.8–95.4)	79.7	(73.9–84.5)	48.6	(42.4–54.8)	66.3	(60.1–72.1)	51.8	(43.3–60.3)
(91.4–97.7)	95.2	` '	94.9	· /	81.9	(76.0-86.7)	48.6	()		(49.5–62.6)	46.5	(37.5–55.7)
(92.9–98.1)	98.4	. ,	97.8	· ,	91.5	(86.5-94.8)	41.6	· /		· ,	54.7	(44.2-64.8)***
,		()		()		· /		. ,		` '		· /
```		( )		( /		( )		( )		( )		(37.9–54.1)
( )		( )		· /		· /		( )		· /		(21.6–39.2)
· · · ·		` '		· /		· /		· /		```		(23.2–41.5)
( )		( )		· /		· /		( /		( )		(30.6–51.7)**
· · · /		. ,		· ,		. ,		( /		` '		(20.3-42.4)**
( )		( )		( )		· · · · · ·		( )		( )		
( )		( )		· ,		```		```		( )		_
( )		( )		( )		( )		()		` '	50 4	(40.9–59.8)
( )		. ,		( )		· · · · · ·		( /		` '		(31.9–50.0)
( /		. ,		· ,		` '		( /		( )		(37.1–56.1)
( )		( )		( /		· /		( )		( )		(25.7–42.6)
( )		( )		· /		( )		```		```		(37.0–57.2)**
( )		( )		· /		( )		( /		```		(27.7–45.7)
	(92.9–98.1) (87.0–93.7) (82.1–90.2) (80.5–90.0) (75.6–86.5) (75.6–87.2) (80.2–91.7) (71.3–86.7) (76.5–87.4) (91.5–97.4) (76.7–87.9) (71.7–83.3) (75.1–85.5) (89.0–95.7)	(92.9-98.1)         98.4           (87.0-93.7)         92.0           (82.1-90.2)         65.2           (80.5-90.0)         82.4           (75.6-86.5)         86.5           (75.6-87.2)         83.9           (80.2-91.7)         86.4           (71.3-86.7)         86.8           (76.5-87.4)         70.2           (91.5-97.4)         94.8           (76.7-87.9)         83.7           (71.7-83.3)         81.3           (75.1-85.5)         72.4           (89.0-95.7)         87.8	(92.9-98.1)         98.4         (96.7-99.3)           (87.0-93.7)         92.0         (88.4-94.5)           (82.1-90.2)         65.2         (59.2-70.7)           (80.5-90.0)         82.4         (76.1-87.3)           (75.6-86.5)         86.5         (81.2-90.5)           (75.6-87.2)         83.9         (76.7-89.3)           (80.2-91.7)         86.4         (79.3-91.3)           (71.3-86.7)         86.8         (79.0-92.0)           (76.5-87.4)         70.2         (63.1-76.5)           (91.5-97.4)         94.8         (91.4-96.9)           (76.7-87.9)         83.7         (76.8-88.8)           (71.7-83.3)         81.3         (75.6-85.9)           (75.1-85.5)         72.4         (66.2-77.8)           (89.0-95.7)         87.8         (82.4-91.6)	(92.9-98.1)         98.4         (96.7-99.3)         97.8           (87.0-93.7)         92.0         (88.4-94.5)         61.0           (82.1-90.2)         65.2         (59.2-70.7)         52.7           (80.5-90.0)         82.4         (76.1-87.3)         72.0           (75.6-86.5)         86.5         (81.2-90.5)         79.4           (75.6-87.2)         83.9         (76.7-89.3)         83.6           (80.2-91.7)         86.4         (79.3-91.3)         86.0           (71.3-86.7)         86.8         (79.0-92.0)         78.2           (76.5-87.4)         70.2         (63.1-76.5)         67.5           (91.5-97.4)         94.8         (91.4-96.9)         93.0           (76.7-87.9)         83.7         (76.8-88.8)         69.4           (71.7-83.3)         81.3         (75.6-85.9)         78.9           (75.1-85.5)         72.4         (66.2-77.8)         66.5           (89.0-95.7)         87.8         (82.4-91.6)         84.4	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$      \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					

* Adolescents (N = 17,835) in the 2008 NIS-Teen were born during January 1990–February 1996.

[†] ≥2 doses of measles, mumps, and rubella vaccine.

§ ≥3 doses of hepatitis B vaccine.

[¶] ≥1 dose of varicella vaccine among adolescents without a reported history of varicella disease.

** Tetanus and diphtheria toxoids vaccine (Td), or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), or tetanus-unknown vaccine on or after age 10 years.

^{+†} ≥1 dose of meningococcal conjugate vaccine or meningococcal-unknown type vaccine. ^{§§} ≥1 dose of quadrivalent human papillomavirus vaccine. Percentage reported among females only (n = 8,607); HPV4 vaccine is not recommended for males.

11 Confidence interval.

*** Estimate might not be reliable; CI width >20.

ttt Estimate not reported because unweighted sample size for the denominator was <30.

protection against varicella (i.e., history of varicella disease or  $\geq 1$  dose of VAR) and Tdap (36.0% versus 41.7%). Overall, the percentage of adolescents with history of varicella or  $\geq 1$  dose of VAR was lower for those living below the poverty level (88.9%) compared with children at or above poverty (93.5%). Compared with whites, coverage was higher among American Indian/Alaska Natives for MMR (93.9% versus 89.9%) and Td/Tdap (81.4% versus 71.6%). Coverage also was higher among Hispanics than whites for  $\geq 1$  dose of MCV4 (46.8% versus 39.7%) and  $\geq 1$  dose of HPV4 (44.4% versus 35.0%). Adolescent females living below the poverty level had a higher vaccination coverage percentage for  $\geq 1$  dose of HPV4 (46.4%) than adolescent females living at or above the poverty level (35.8%).

*Healthy People 2010* established vaccination coverage targets of 90% for adolescents aged 13–15 years for ≥3 doses of HepB, ≥2 doses of MMR, ≥1 dose of Td or Tdap, and ≥1 dose of VAR, among those without history of disease (5). For the first time, *Healthy People 2010* targets were achieved for ≥3 doses of HepB (91.8%, CI = 90.7–92.8) and ≥2 doses of MMR (90.7%, CI = 89.6–91.8). Vaccination coverage remained stable at 70.7% (CI = 69.0–72.4) for ≥1 dose of Td or Tdap, and increased from 80.2% in 2007 to 85.5% (CI = 83.5–87.3) in 2008 for ≥1 dose of VAR.

**Reported by:** S Stokley, MPH, C Dorell, MD, D Yankey, MS, Immunization Svc Div, National Center for Immunization and Respiratory Diseases, CDC.

#### 1000

# TABLE 3. Estimated vaccination coverage among adolescents aged 13–17 years,* by race/ethnicity,[†] poverty level,[§] and selected vaccines and doses — National Immunization Survey–Teen, United States, 2008

					Rac	e/Ethnicity						Poverty s	status	
		White = 12,628)	Black (n = 1,934)		Hispanic (n = 2,017)		Ala	ican Indian/ ska Native n = 234)	Asian (n = 334)		Below poverty level (n = 2,140)		At or above poverty leve (n = 14,951)	
Vaccines and doses	%	(95% CI [¶] )	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
MMR** ≥2 doses	89.9	(88.8–90.8)	89.1	(86.5–91.2)	87.5	(84.4–90.0)	93.9	(88.3–96.9)††	87.2	(77.4–93.1)	87.1	(84.1–89.6)	89.6	(88.6-90.6)
Hepatitis B ≥3 doses	88.1	(87.0-89.1)	86.0	(83.3–88.3)	89.8	(87.0–92.0)	86.6	(77.6–92.4)	89.9	(80.0–95.2)	86.7	(83.9–89.1)	88.0	(87.0-89.1)
Varicella History of varicella disease ^{§§}	63.1	(61.6–64.6)	53.5	(49.2–57.7)††	55.1	(50.5–59.7)††	66.2	(54.0–76.5) ^{¶¶}	58.2	(48.1–67.6)	51.5	(47.0–55.9)††	61.8	(60.3–63.3)
Among adolescents without history of disease ≥1 dose ≥2 doses History of disease or received ≥1 dose	82.8 31.6 93.7	(81.0–84.5) (29.5–33.9) (93.0–94.3)	74.0 35.0 87.9	(68.4–78.9) ^{††} (28.1–42.6) (85.1–90.2) ^{††}	84.5 38.5 93.0	(31.8–45.7)	83.5 94.4	(68.4–92.2) ¹¹¹ *** (88.9–97.3)	36.1	(82.0–93.6) (24.0–50.3) ^{¶¶} (92.4–97.3)	77.0 35.8 88.9	(71.1–82.1) ^{††} (28.9–43.4) (85.8–91.3) ^{††}	82.9 33.9 93.5	(81.2–84.4) (31.5–36.3) (92.8–94.1)
varicella vaccine Td or Tdap since age 10 vears ¹¹¹														
≥1dose Td or Tdap ≥1dose Tdap	71.6 41.7	(70.1–73.0) (40.2–43.3)	71.4 36.0	(67.6–74.9) (31.9–40.2) ^{††}	74.1 41.9	(70.0–77.8) (37.5–46.5)	81.4 43.5	(72.6–87.8) ^{††} (31.7–56.1) ^{¶¶}		(67.2–84.4) (34.4–54.9) ^{¶¶}	70.9 38.6	(67.0–74.4) (34.2–43.2)	72.7 41.2	(71.3–74.1) (39.7–42.8)
MCV4 ≤1 dose ^{§§§}	39.7	(38.2–41.2)	43.1	(39.0–47.3)	46.8	(42.2–51.4)††	47.3	(35.4–59.5)¶¶	50.5	(40.3–60.8) ^{¶¶}	40.8	(36.6–45.2)	42.0	(40.5-43.6)
HPV4 ^{៕៕} ≥1 dose ≥3 doses	35.0 19.5	(32.9–37.1) (17.8–21.3)	35.7 14.9	(29.5–42.4) (9.7–22.3)	44.4 14.7	(38.0–50.9) ^{††} (11.4–18.8) ^{††}	52.8	(35.4–69.6) ^{¶¶} —	40.6	(27.6–55.2) ^{¶¶} —	46.4 14.9	(39.8–53.1) ^{††} (9.6–22.2)	35.8 18.6	(33.7–37.9) (17.0–20.3)

* Adolescents (N = 17,835) in the 2008 NIS-Teen were born during January 1990-February 1996.

[†] Respondents who self-identified as white, black, Asian, or American Indian/Alaska Native were all considered non-Hispanic. Persons who self-identified as Hispanic might be of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races (n = 688) were not included because of small sample sizes.

§ Adolescents were classified as below poverty level if their total family income was less than the federal poverty level specified for the applicable family size and number of children aged <18 years. All others were classified as at or above the poverty level. Additional information available at http://www.census.gov/hhes/www/poverty.html. Poverty status was unknown for 744 adolescents.

[¶] Confidence interval.

** Measles, mumps, and rubella vaccine.

⁺⁺ Statistically significant difference at p<0.05 in estimated vaccination coverage. For race/ethnicity, referent group was white, non-Hispanic adolescents; for poverty status, referent group was at or above poverty level.

§§ By parent/guardian report or provider records.

¹¹ Estimate might not be reliable; CI width >20.

*** Estimate not reported because unweighted sample size for the denominator was <30.

ttt Tetanus and diphtheria toxoids vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap), or tetanus-unknown type vaccine.

§§§ Includes percentages receiving meningococcal conjugate vaccine (MCV4) or meningococcal-unknown type vaccine.

111 Quadrivalent human papillomavirus vaccine. Percentages reported among females only (n = 8,607); HPV4 vaccine is not recommended for males.

**Editorial Note:** This is the third annual report of national adolescent vaccination coverage based on provider-reported vaccination histories from NIS-Teen and the first report of state and local area estimates. Coverage levels for vaccines routinely recommended for adolescents continued to increase nationally; however, coverage varied substantially among state and local areas. Differences also were observed by race/ethnicity and poverty status including higher HPV4 ( $\geq 1$  dose) coverage among Hispanic females compared with whites and among adolescents living below compared with those living at or above the poverty level.

The wide variation in adolescent coverage levels among states might be the result of changes in immunization policies, recent experiences with outbreaks of vaccine preventable diseases, or efforts to remove cost as a barrier to vaccination. For example, Colorado, a state with high Tdap coverage, implemented a Tdap requirement for 6th and 10th grade students during the 2007–08 school year, incrementally increasing the grades covered until 2011, when the requirement will apply to all students in grades 6–12 (J. Reynolds, Colorado Immunization Program, personal communication, 2009). During the 2007–08 school year, 22 states reported having a requirement for a tetanuscontaining vaccine for entry into middle school (only seven specified Tdap formulation); no states reported requirements for MCV4 or HPV4 vaccines.^{††} In New Hampshire, an increase in funds contributed by insurance companies for state purchase of vaccine soon after HPV4 was recommended allowed the state to provide universal coverage to females aged 11–18 years (M. Bobinsky, New Hampshire Immunization Program, personal communication, 2009). However, in 2008, only seven states provided universal coverage of all routinely

^{††} Additional information available at http://www2a.cdc.gov/nip/schoolsurv/ combinedlaws2007.pdf.

recommended pediatric vaccines for all children.^{§§} Further evaluation of NIS-Teen data is needed to assess the impact state middle school requirements and vaccine-financing policies have on adolescent vaccination coverage.

Among vaccines routinely recommended for adolescents, coverage with  $\geq 1$  dose of HPV4, which was approved only 2 years before the survey, had the greatest percentage-point increase (12.1) in vaccination coverage from 2007 to 2008. The percentage of females initiating the HPV4 series was 9.4 percentage points higher among Hispanics compared with whites and 10.6 percentage points higher among those who live below the poverty level than those who live at or above the poverty level. These findings are important because certain HPV infections are a major cause of cervical cancer and Hispanic adult females and those who live below the poverty level tend to have lower cervical cancer screening rates and higher rates of cervical cancer incidence and mortality (4).

Why HPV4 vaccination coverage was higher among Hispanic adolescent females than whites was not clear. However, among survey participants, a much greater percentage of Hispanic adolescents were living below the poverty level (43.2%) than whites (6.7%). Higher coverage for the first dose of HPV4 among adolescents living below the poverty level might be explained by vaccine financing concerns. Because HPV4 is the most expensive vaccine recommended for adolescents (6), its availability through the Vaccines for Children (VFC) program has removed cost as a barrier to receiving HPV4 among VFC-eligible adolescents (i.e., adolescents who are uninsured, Medicaid eligible, or of American Indian/Alaska Native descent). Financial barriers to purchasing and administering HPV4 vaccine have been reported among private health-care providers (7), which might account for the lower coverage observed among adolescents who live at or above the poverty line and are more likely to be privately insured. Differences by poverty status were not observed for 3-dose HPV4 coverage; however, coverage overall was low (17.9%). Barriers other than cost might affect the ability of adolescent females to complete the HPV4 series, and further studies are needed to understand and address the barriers to receiving all of the recommended doses of HPV4.

The findings in this report are subject to at least four limitations. First, NIS-Teen is a landline telephone survey; although studies indicate that statistical adjustments adequately compensate for exclusion of households without telephones (8), sampling bias might remain. Second, underestimates of vaccination coverage might have resulted from the exclusive use of provider-verified vaccination histories because completeness of these records is unknown. Third, sample sizes were insufficient to adequately compare vaccine coverage rates among racial/ethnic groups stratified by poverty status. Finally, annual estimates for state and local areas and by racial/ethnic groups should be interpreted with caution because of smaller sample sizes and wider confidence intervals.

CDC will continue to monitor vaccination coverage among adolescents annually, enabling further analysis of coverage trends by race/ethnicity, poverty status, and geographic area. Results from a systematic review in 2000 identified several strategies shown to improve vaccination coverage among children, adolescents, and adults, including 1) client and provider reminder, 2) vaccination requirements for school attendance, 3) reduction of out-of-pocket costs, 4) increased vaccination access in health-care settings, and 5) assessment and feedback to vaccination providers (9). The majority of studies from which these efforts were identified targeted infant vaccination; therefore, additional research to identify evidence-based strategies for improving vaccination coverage among adolescents specifically will be needed to achieve high coverage levels in this population.

## References

- 1. CDC. Recommended immunization schedules for persons aged 0–18 years—United States. 2009. MMWR 2008;57(51&52).
- Jain N, Singleton JA, Montgomery M, Skalland B. Determining accurate vaccination coverage rates for adolescents: the National Immunization Survey-Teen 2006. Public Health Rep 2009;124:642–51.
- CDC. Vaccination coverage among adolescents aged 13–17 years—United States, 2007. MMWR 2008;57:1100–3.
- CDC. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-2).
- 5. US Department of Health and Human Services. Objective 14-27: increase routine vaccination coverage levels for adolescents. Healthy people 2010 (conference ed, in 2 vols). Washington, DC: US Department of Health and Human Services; 2000. Available at http://www.healthypeople.gov/ document/html/objectives/14-27.htm.
- CDC. CDC vaccine price list. September 2, 2009. Available at http:// www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm.
- 7. Freed GL, Cowan AE, Clark SJ. Primary care physician perspectives on reimbursement for childhood immunizations. Pediatrics 2008; 122:1319–24.
- Molinari N, Wolter KM, Skalland B, et al. Quantifying bias in a health survey: an application of total survey error modeling to the National Immunization Survey. Presented at the annual meeting of the American Association for Public Opinion Research, May 14–17, 2009, Hollywood, FL.
- Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med 2000;18(1 suppl):97–140.

^{§§} Additional information available at http://www.cdc.gov/vaccines/programs/ vfc/projects/data/vacc-supply-public-2008.htm.

# Update on Vaccine-Derived Polioviruses – Worldwide, January 2008–June 2009

In 1988, the World Health Assembly resolved to eradicate poliomyelitis worldwide (1). Subsequently, the Global Polio Eradication Initiative of the World Health Organization (WHO) reduced the global incidence of polio associated with wild polioviruses (WPVs) from an estimated 350,000 cases in 125 countries in 1988 to 1,651 reported cases in 2008 and reduced the number of countries that have never interrupted WPV transmission to four (Afghanistan, India, Nigeria, and Pakistan) (1). Under current WHO plans, when the goal of eradicating all WPV transmission is attained, oral poliovirus vaccine (OPV) use worldwide eventually will be discontinued. However, because vaccine-derived polioviruses (VDPVs) can produce polio outbreaks in areas with low rates of Sabin OPV coverage and can replicate for years in immunodeficient persons, enhanced strategies are needed to limit emergence of VDPVs (2). This report updates previous summaries (3,4) and describes VDPVs detected worldwide during January 2008–June 2009. During this period, 1) two new outbreaks of circulating VDPVs (cVDPVs) (accounting for 4-20 cases) were identified in the Democratic Republic of Congo and Ethiopia; 2) a previously identified outbreak in Nigeria ultimately resulted in a cumulative total of 292 cases; 3) two newly identified paralyzed immunodeficient persons in Argentina and the United States were found to excrete VDPVs; and 4) isolated VDPVs were found among persons and environmental samples in 11 countries. All countries need to maintain 1) high rates of poliovirus vaccination coverage to prevent VDPV spread and 2) sensitive poliovirus surveillance to detect VDPVs.

# **Properties of VDPVs**

VDPVs can cause paralytic polio in humans and have the potential for sustained circulation. VDPVs resemble WPVs biologically (2) and differ from most Sabin vaccine-related poliovirus (VRPV) isolates by having genetic properties consistent with prolonged replication or transmission. Because poliovirus genomes evolve at a rate of approximately 1% per year, Sabin VRPV isolates that differ from the corresponding OPV strain by >1% of nucleotide positions (usually determined by sequencing the genomic region encoding the major viral surface protein, VP1) are estimated to have replicated for at least 1 year in one or more persons after administration of an OPV dose. This is substantially longer than the normal period of vaccine virus replication of 4–6 weeks in an OPV recipient. Poliovirus isolates are divided into three serotypes: type 1, type 2, and type 3. Isolates are divided further into three categories, based on the extent of VP1 nucleotide sequence divergence from the corresponding Sabin OPV strain: 1) Sabin VRPVs ( $\leq 1\%$  divergent), 2) VDPVs (VRPVs that are >1% divergent from the corresponding Sabin strain), and 3) WPVs (no genetic evidence of derivation from any vaccine strain) (3). VDPVs are further categorized as 1) circulating VDPVs (cVDPVs), when evidence of person-to-person transmission in the community exists; 2) immunodeficiency-associated VDPVs (iVDPVs), which are isolated from persons with primary immunodeficiencies who have prolonged VDPV infections; and 3) ambiguous VDPVs (aVDPVs), which are either clinical isolates from persons with no known immunodeficiency or sewage isolates whose ultimate source is unknown (2).

# Virologic Testing for VDPVs

Soon after the recognition of a cVDPV outbreak in Hispaniola in 2001 laboratories of the Global Polio Laboratory Network (GPLN) implemented a protocol to screen for VDPVs, using a combination of molecular and antigenic methods. VRPV isolates identified by molecular methods that had "non– vaccine-like" antigenic properties were candidate VDPVs and were sequenced (2). However, since 2007, some VDPVs, especially less divergent type 2 VDPV (VDPV2) isolates, have undergone limited antigenic evolution and were missed by this screening protocol. A new method based on real-time reverse transcription–polymerase chain reaction (rRT-PCR), which targets nucleotide substitutions that occur early in VDPV emergence, has been evaluated and shown to detect VDPVs with much higher sensitivity and is being implemented as a routine screening method by GPLN as of 2009 (*5*).

# **cVDPV**s

**Democratic Republic of Congo.** Retrospective and ongoing characterization of Sabin 2-related isolates by rRT-PCR found 20 acute flaccid paralysis (AFP) cases associated with cVDPV2 (1.1%-2.0% divergent) during 2005–2009 (Figure). Most (n = 15) cases occurred in Katanga Province during 2008–2009, but others occurred in Bandundu (n = 2) in 2005, Sud-Kivu (n = 1) in 2007, Orientale (n = 1) in 2007, and Kasai-Occidental (n = 1) in 2008. The Katanga and Kasai-Occidental isolates had diverged into two main clusters of related lineages, whereas the remaining isolates were unlinked genetically. An additional 13 Sabin 2-related isolates with 0.6%–1.0% VP1 divergence were found in Katanga and elsewhere, some of which clustered geographically and genetically with outbreak viruses.




FIGURE. Vaccine-derived polioviruses (VDPVs) detected worldwide, January 2008–June 2009

* Immunodeficiency-associated VDPV.

[†] Ambiguous VDPV.

[¶] Circulating VDPV.

** Spread of cVDPVs followed the elimination of the corresponding serotype of indigenous wild poliovirus, but with continued introduction of oral poliovirus vaccine into communities with growing immunity gaps. All of the cVDPV outbreaks were detected first by the laboratory, using sequence data and evolutionary analyses.

**Ethiopia.** Four closely-related cVDPV2 isolates (1.1%–1.2% divergent) were isolated during October 2008 and February 2009 from AFP patients in East Harerghe.

**Guinea.** A girl aged 6 years, who had received 1 dose of OPV in 2003 and was living in a camp for refugees from Côte d'Ivoire, had AFP onset in May 2009. A VDPV2 (3.5% divergent) was isolated and was found to be closely related to several 2008–2009 cVDPV2 isolates from northern Nigeria.

**Nigeria.** Since 2005, 292 AFP cases associated with an outbreak of cVDPV2 have been reported in 11 northern and three central states of Nigeria. The outbreak is ongoing, with one case in 2005, 20 in 2006, 68 in 2007, 63 in 2008, and 140 during January–June 2009. Twenty-eight percent (81 of 292) of all cVDPV isolates were from Kano state, which has been a major reservoir for WPV type 1 (WPV1) and WPV3 circulation within Nigeria (*1*,*3*). However, the proportion of cVDPV cases occurring outside of Kano increased to 81% during January 2008–June 2009. Genetic analysis of outbreak viruses indicated that the detected cases actually represent several concurrent outbreaks arising from multiple independent cVDPV2 emergences during 2004–2006.

VDPV circulation was largely limited to the northern Nigerian states, where WPV1 and WPV3 circulation has continued (1). Two independent introductions of cVDPV2 into the Republic of Niger from Nigeria were detected in 2006 (3), and an introduction into Guinea was found in 2009. By comparison, WPV1 and WPV3 from Nigeria have spread widely in neighboring countries of Africa (6).

Of the 26 targeted supplementary immunization activities (SIAs)* conducted in Nigeria since 2006, 16 have used monovalent OPV type 1 (mOPV1), five have used mOPV3, and sixhave used trivalent OPV (tOPV) (most recently during May 30–June 2, 2009 [as of June 30, 2009]). Routine immunization uses tOPV, but its use is estimated to be only 61% nationwide and much lower in the northern states.

# **iVDPV**s

Since the introduction of OPV in 1961, approximately 40 persons with B-cell immunodeficiencies have been found

[§] Acute flaccid paralysis.

^{*} Mass campaigns conducted during a short period (days to weeks) during which a dose of OPV is administered to all children aged <5 years, regardless of previous vaccination history. Campaigns can be conducted nationally or in portions of the country.

to be excreting iVDPVs, which are indicative of prolonged infections. Currently, no effective therapies to clear iVDPV infections are available.

**Argentina.** A boy aged 15 months with x-linked agammaglobulinemia, who had received three OPV doses in his first months of life, developed AFP in April 2009. iVDPV1 (3.6%– 3.8% divergent) was isolated from two serial stool specimens. No other VDPVs were detected among 87 contacts tested.

**United States.** OPV use in the United States ceased after 1999.[†] In December 2008, a woman aged 44 years with a >20 year history of common-variable immunodeficiency developed ascending paralysis in all limbs and respiratory insufficiency. She died in March 2009 from various complications of her chronic illness, including neurologic sequelae. Highly divergent (12.3%) iVDPV2 was isolated from a pre-mortem stool specimen. A household member had received three OPV doses 13 years before onset of AFP in the decedent, and the estimated age of the iVDPV2 suggests that one of those doses could have been the source of exposure. This infection is independent of the VDPV1 that circulated in an undervaccinated rural Minnesota community in 2005 (7).

# aVDPVs

aVDPVs have been isolated in 11 countries during January 2008–June 2009 (Table). Descriptions of the most divergent aVDPVs, all from sewage samples, follow.

**Estonia.** Highly divergent (approximately 15%) aVDPV2 and aVDPV3 were isolated from separate sewage samples taken in September and December 2008. The isolates had sequence properties that suggested that they originated from a common infection, and the aVDPV3 is related to another Estonian aVDPV3 isolated from sewage described previously (*2*,*8*).

**Finland.** Highly divergent (approximately 15%) aVDPV1, aVDPV2, and aVDPV3 were isolated from sewage samples collected in Tampere in December 2008 and June 2009. The isolates had sequence properties that suggested that they originated from a common infection. The Finnish aVDPVs are distinct from the Estonian aVDPVs.

**Israel.** Environmental monitoring for polioviruses was implemented by Israel after its 1987–1988 WPV1 outbreak. Monitoring sewage samples from the Tel Aviv area (sampling populations of approximately 350,000 and 10,000) yielded two groups of type 2 aVDPVs (9). The first group was detected initially in 1998, and 19 more highly divergent

representatives (approximately 15% divergent) were detected during 2008–2009. The second group, detected since 2006, is less divergent (approximately 7%) and is defined by 10 isolates. Despite follow-up investigations, no source for these VDPVs has been identified. An aVDPV1 (8.2% divergent) was isolated from an environmental sample collected from a site sampling a different population in Haifa on February 22, 2009.

**Reported by:** Polio Eradication Dept, World Health Organization, Geneva, Switzerland. Div of Viral Diseases, Global Immunization Div, National Center for Immunization and Respiratory Diseases, CDC.

Editorial Note: The recent VDPV emergences reinforce some key lessons for the Global Polio Eradication Initiative. The cVDPV2 outbreak in Nigeria, whose 4-year duration is surpassed only by the decade-long cVDPV2 outbreak in Egypt during 1983–1993 (10), further demonstrates that cVDPVs, like WPV, can circulate indefinitely in settings with low rates of poliovirus vaccination coverage. The emergence of multiple independent cVDPV2 lineages in Nigeria and the unrelated cVDPV2 outbreaks in the Democratic Republic of Congo and Ethiopia highlight the particular risks for emergence of cVDPV2 in settings of low tOPV coverage (10). Improvements in laboratory methods for the identification of VDPV2 facilitated early detection of the outbreaks in the Democratic Republic of Congo and Ethiopia, but maintenance of sensitive AFP surveillance was crucial; any temporal and geographic clustering of vaccine-related isolates of the same serotype should prompt further investigation.

The appearance of an iVDPV case in the United States 13 years after the likely exposure and 9 years after cessation of OPV use illustrates the continued risk among immunodeficient persons from past OPV use. Chronic iVDPV excretors (i.e., excretion for >5 years) have been described in several countries that have shifted to inactivated poliovirus vaccine (IPV) (2), and the highly divergent aVDPVs found in sewage in Israel, Estonia, and Finland have similar genetic properties to iVDPVs from chronic excretors. The appearance of an iVDPV case in Argentina further underscores the risks of prolonged iVDPV excretion in middle-income countries (2,3).

Several of the aVDPVs described in this report show only limited divergence (1.1%–1.5%) and were detected after implementation of the new rRT-PCR screening methods. In some settings such isolates are observed sporadically, and no genetically linked VDPVs are found subsequently. However, in settings of potential low local tOPV coverage, the sporadic detection of aVDPVs should prompt further clinical investigation (when the patient is identified), review of surveillance and polio vaccination coverage data, and implementation of

[†]Additional information available at http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr4905a1.htm.

#### TABLE. Vaccine-derived polioviruses (VDPVs) detected worldwide, January 2008–June 2009

						No. of isola	ates†	VP1 divergence	Routine coverage	Estimated	Current status (date of last outbreak case,
Category	Country	Year(s) detected*	Source	Sero- type		Contacts	Environ- mental samples	from Sabin OPV [§] strain (%)	with 3 doses of poliovirus vaccine (%) [¶]	duration of VDPV replication**	last patient isolate, or last environ- mental sample)
cVDPV ^{††}	Nigeria ^{§§}	2005–2009	Outbreak (292 cases) ^{¶¶}	2	292	_	_	1.0–5.1	61	5 yrs	June 27, 2009
	Guinea	2009	Importation (1 case)***	2	1	—	—	3.5	71	—	May 12, 2009
	Democratic Republic of Congo	2005–2009	Outbreak (20 cases) ^{¶¶}	2	33	_	—	1.0–2.0	68	4 yrs	March 7, 2009
	Ethiopia	2008–2009	Outbreak (4 cases)	2	4	—	—	1.2	75	1 yr	February 16, 2009
iVDPV ^{†††}	Argentina	2009	AFP ^{§§§} patient (XLA ¹¹¹¹⁾ )	1	1	—	2	3.6–3.8	94	≥15 mos	Alive (April 23, 2009)
	United States	2009	AFP patient (CVID****)	2	1	—	—	12.3	96 (IPV ^{††††} )	13 yrs	Died in March 2009
aVDPV§§§§	Angola	2008	AFP patient	2	1	_	_	1.1	75	1 yr	May 5, 2008
	0	2008	AFP patient	2	1	_	_	1.1		1 yr	May 25, 2008
	China	2009	AFP patient	2	1	_	_	1.2	99	1 yr	February 22, 2009
	Egypt	2008	Environment	2	_		1	1.7	97	1.5 yrs	April 7, 2008
	Estonia	2008	Environment	2	_	_	1	14.5	95	>15 yrs	September 25, 2008
		2008	Environment	3	_		1	15.6		>15 yrs	December 29, 2008
	Ethiopia	2009	AFP patient	3	1	_	_	1.3	75	1 yr	April 30, 2009
	Finland	2008–2009	Environment	1	_	_	1 1111	12.4	97 (IPV)	13 yrs	December 15, 2008
		2008–2009	Environment	2	_	_	1	12.7		13 yrs	December 15, 2008
		2009	Environment	3	_	_	1	14.6		14 yrs	June 26, 2009
	India	2009	AFP patient	1	1	_	_	1.1	66	1 yr	April 7, 2009
		2009	AFP patient	2	1	_	_	1.3		1 yr	April 30, 2009
		2009	AFP patient	2	1	_	_	1.1		1 yr	June 29, 2009
		2009	Environment	3	_	_	1	1.2		1 yr	May 20, 2009
	Israel	2009	Environment	1	_	_	1	8.2	95 (IPV)	8 yrs	February 22, 2009
		1998–2009	Environment	2	_	_	33****	8.8–15.3		>15 yrs	January 20, 2009
		2006–2009	Environment	2	_	_	10*****	6.6–9.7		10 yrs	November 25, 2008
	Malawi	2008†††††	AFP patient	3	1	_	_	3.1	92	3 yrs	January 14, 2008
	Russia	2008	Healthy child	1	1	_	_	1.4	98 (IPV)	1 yr	Alive (March 2008)
	Somalia	2008	AFP patient	2	1	_	_	1.1	24	1 yr	April 5, 2008
		2008	AFP patient	2	1	1	—	1.6		1 yr	June 24, 2008
	Switzerland	2008	Environment	2	_	_	1	1.2	95 (IPV)	1 yr	January 2008
		2008	Environment	1	_	_	1	1.1		1 yr	March 2008

* Total years detected and cumulative totals for the previously reported cVDPV outbreak (Nigeria).

[†] Includes environmental aVDPV isolates (Israel).

§ Oral poliovirus vaccine.

¹ Based on 2008 data from the World Health Organization (WHO) Vaccine Preventable Diseases Monitoring System (2009 global summary) and WHO-UNICEF coverage estimates, available at http://www.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm. National data might not reflect weaknesses at subnational levels.

^t Duration of cVDPV circulation was estimated from extent of VP1 nucleotide divergence from the corresponding Sabin OPV strain; duration of immunodeficiency-associated VDPV replication was estimated from clinical record by assuming that exposure was from initial receipt of OPV; duration of ambiguous VDPV replication was estimated from sequence data.

⁺⁺ Circulating VDPV. Most cVDPV isolates from Nigeria, Democratic Republic of Congo, Ethiopia, and Guinea were vaccine/nonvaccine recombinants. §§ Previously reported outbreak; OPV coverage <50% around cases.

11 Excludes isolates 0.5%-1.0% divergent from Sabin 2 that are closely related to the cVDPV isolates: 16 from Nigeria and 13 from Democratic Republic of Congo. Some of the isolates formed genetic lineages.

**** Importation from Nigerian cVDPV outbreak. Isolate shared >60% of nucleotide differences from Sabin 2 with cVDPV isolates from northern Nigeria.

ttt Immunodeficiency-associated VDPV. None of the iVDPV isolates appeared to be vaccine/nonvaccine recombinants.

§§§ Acute flaccid paralysis.

1111 X-linked agammaglobulinemia.

**** Common variable immunodeficiency.

tttt Inactivated poliovirus vaccine.

\$\$\$\$ Ambiguous VDPV. None of the aVDPV isolates appeared to be vaccine/nonvaccine recombinants.

1111 Types 1 and 2 aVDPVs were isolated from the same environmental sample.

***** Two separate lineages of type 2 aVDPVs were isolated from environmental samples in Israel.

ttttt AFP onset on December 23, 2007.

vaccination campaigns (mop-ups and SIAs, usually with tOPV) to prevent virus spread.

Experience has underscored the importance of routine immunization either with IPV or tOPV to prevent VDPV spread (10). In countries with low rates of routine vaccination, closing the immunity gaps to all three poliovirus serotypes by periodic but regular use of tOPV in SIAs is important. However, high rates of tOPV coverage will not prevent or clear VDPV infections in immunodeficient hosts. WHO, in collaboration with other partners, is exploring antiviral compounds for their potential to clear iVDPV infections (3).

#### References

- CDC. Progress toward interruption of wild poliovirus transmissionworldwide, 2008. MMWR 2009;58:308–12.
- 2. CDC. Update on vaccine-derived polioviruses. MMWR 2006;55: 1093–7.
- CDC. Update on vaccine-derived polioviruses—worldwide, January 2006–August 2007. MMWR 2007;56:996–1001.
- CDC. Laboratory surveillance for wild and vaccine-derived polioviruses —worldwide, January 2007–June 2008. MMWR 2008;57:967–70.
- CDC. Laboratory surveillance for wild and vaccine-derived polioviruses —worldwide, January 2008–June 2009. MMWR 2009;58:950–4.
- 6. CDC. Wild poliovirus type 1 and type 3 importations—15 countries, Africa, 2008–2009. MMWR 2009;58:357–62.
- Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an under-vaccinated community— Minnesota, USA. J Infect Dis 2009;199:391–7.
- Blomqvist S, Savolainen C, Laine P, et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol 2004;78:4876–83.
- 9. Shulman LM, Manor Y, Sofer D, et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One 2006;1:e69.
- Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587–635.

# Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Hepatitis A Vaccine in Close Contacts of Newly Arriving International Adoptees

On February 25, 2009, the Advisory Committee on Immunization Practices (ACIP) recommended routine hepatitis A vaccination for household members and other close personal contacts (e.g., regular babysitters) of adopted children newly arriving from countries with high or intermediate hepatitis A endemicity. This new recommendation complements previous ACIP recommendations for hepatitis A vaccination for persons traveling from the United States to countries with high or intermediate hepatitis A endemicity (1,2) (including persons with travel related to international adoption), and postexposure prophylaxis for contacts of persons with hepatitis A (1). This report introduces the new recommendation and outlines the underlying epidemiologic and programmatic rationale.

# **Rationale and Methods**

Hepatitis A virus (HAV) can produce either asymptomatic or symptomatic infection in humans after an average incubation period of 28 days (range: 15-50 days) (3). Peak infectivity occurs during the 2-week period before onset of jaundice or elevation of liver enzymes, when concentration of virus in stool is highest (4). Illness caused by HAV typically has an abrupt onset that can include fever, malaise, anorexia, nausea, abdominal discomfort, dark urine, and jaundice. The likelihood of having symptoms with HAV infection increases with age. Fewer than 10% of infections among children aged 0-4 years result in jaundice; this percentage increases to 30%–40% among children aged 5-9 years, 60%-80% among youths aged 10–17 years, and 80%–90% among adults aged ≥18 years (5). When signs and symptoms occur, typically they last <2 months, although 10%–15% of symptomatic persons have prolonged or relapsing disease lasting up to 6 months (6). The case-fatality rate for HAV infection increases with age: 1.8% for persons adults aged >50 years compared with 0.6% for persons aged <50 years. The case-fatality rate is also increased among persons with chronic liver disease, who are at increased risk for acute liver failure (7).

In making its recommendation, ACIP considered the likelihood that a child adopted by parents in the United States might be actively infected with HAV and shedding virus at the time of adoption. During 1998–2008, approximately 18,000 children (range: 15,583 to 22,884) were adopted from foreign countries by families in the United States each year.* Approximately 99.8% of these children came from countries where hepatitis A is considered to be of high or intermediate endemicity (2), and approximately 85% of were aged <5 years. Country-specific policies pertaining to foreign adoption are changing constantly, leading to rapid changes in the numbers of international adoptees entering the United States from various countries. Although South Korea was the most common country of origin for adoptions in the United States in the early 1990s, Russia and China became prominent in international adoption in the late 1990s, and currently the largest numbers

^{*} Additional information available at http://adoption.state.gov/news/total_chart. html.

of adopted children come from Guatemala, China, Russia, and Ethiopia. The incidence of HAV infection is highest in these countries among children aged <5 years, when HAV infection is likely to be asymptomatic.

ACIP also considered recent reports of HAV infection among persons in close contact with new adoptees from countries of high or intermediate hepatitis A endemicity. Such persons are at greater risk for HAV infection. In 2007, CDC was notified of a case of fulminant hepatitis A in a nontraveling household contact of an asymptomatic Ethiopian adoptee confirmed to have acute hepatitis A (immunoglobulin M [IgM] antibody to HAV [anti-HAV] positive). This case prompted further investigation that led to identification of 20 other cases of acute hepatitis A among persons who had close personal contact with newly arriving internationally adopted children and no history of traveling abroad (8). Two acute hepatitis A cases were identified among traveling parents who had not been vaccinated. This same study found that 98% of parents traveling to pick up their children had been vaccinated against hepatitis A in accordance with existing ACIP recommendations (8).

Since 2007, CDC has received 14 additional reports of acute hepatitis A following exposure to nonjaundiced adoptees newly arriving from countries of high or intermediate hepatitis A endemicity. Although these numbers are small compared with the total number of hepatitis A cases (2,979) reported to CDC in 2007 (9), they likely represent an underestimate of the number of hepatitis A cases associated with international adoptions because contact with an international adoptee is not asked routinely as part of national hepatitis A surveillance. All of the 14 adoptee-associated cases identified since 2007 were in close contacts who had not been vaccinated against hepatitis A and had no history of travel and no other risk factors for hepatitis A. In one instance, both adoptive parents developed hepatitis A that required hospitalization (CDC, unpublished data, 2008). In another instance, a 2008 community outbreak with 12 hepatitis A cases was associated with an asymptomatic HAV-infected international adoptee; two infected contacts were hospitalized, and disease was identified among tertiary contacts in an elementary school (CDC, unpublished data, 2009).

Data from a study conducted at three adoption clinics in the United States, each screening 100–200 incoming adoptees for hepatitis A each year, indicate that 1%–6% of newly arrived international adoptees are acutely infected with HAV (non-jaundiced; IgM anti-HAV positive). A proportion of these adoptees represent a source of infection for susceptible close contacts (9). The risk for hepatitis A among close personal

contacts of international adoptees is estimated at 106 (range: 90–819) per 100,000 household contacts of international adoptees within the first 60 days of their arrival in the United States (CDC, unpublished data, 2009). By comparison, according to surveillance data, the estimated rate of symptomatic hepatitis A in the U.S. general population in 2007 was 1.0 per 100,000 population (*10*).

# **Updated Recommendation**

Based on this evidence, on February 25, ACIP updated its guidance by recommending hepatitis A vaccination for all previously unvaccinated persons who anticipate close personal contact (e.g., household contact or regular babysitting) with an international adoptee from a country of high or intermediate endemicity during the first 60 days following arrival of the adoptee in the United States. The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.

# References

- CDC. Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56:1080–4.
- CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-7).
- Krugman S, Giles JP. Viral hepatitis: new light on an old disease. JAMA 1970;212:1019–29.
- Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, Purcell RH. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 1986;154:231–7.
- Armstrong GL and Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002;109:839–45.
- 6. Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A: review of 14 cases and literature survey. Medicine 1992;71:14–23.
- Williams I, Bell B, Kaluba J, Shapiro C. Association between chronic liver disease and death from hepatitis A, United States, 1989–92 [abstract no. A39]. IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy, April 21–25, 1996.
- Fischer GE, Teshale EH, Miller C, et al. Hepatitis A among international adoptees and their contacts. Clin Infect Dis 2008;47:812–4.
- Advisory Committee on Immunization Practices. ACIP presentation slides: February 2009 meeting. Hepatitis vaccines. Available at http:// www.cdc.gov/vaccines/recs/acip/slides-feb09.htm#hev.
- 10. CDC. Surveillance for acute viral hepatitis—United States, 2007. MMWR 2009;58(No. SS-3).

# Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine

On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of *H. influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conjugated to inactivated tetanus toxoid (PRP-T). Hiberix is licensed for use as the booster (final) dose of the Hib vaccine series for children aged 15 months through 4 years (before the 5th birthday) who have received previously the primary series of Hib vaccination (consisting of 2 or 3 doses, depending on the formulation) (1). The Advisory Committee on Immunization Practices (ACIP) recommends Hib booster vaccination for children at ages 12 through 15 months; however, because of the recent shortage of Hib vaccines, many children have deferred the booster dose and therefore require catch-up vaccination (2). This report summarizes the indications for Hiberix use and provides guidance on Hib booster dose administration based on increasing vaccine supplies. Vaccination recommendations in this report update the previous advisory on Hib booster administration (June 26, 2009) (2), which advised that children with deferred booster doses receive it at the next regularly scheduled visit. Vaccination providers are now recommended to begin recall of children in need of the booster dose when feasible and monovalent Hib vaccine supply in the office is adequate.

# **Hiberix Licensure**

FDA licensed the new vaccine after review of safety and immunogenicity data from seven core studies conducted outside the United States that evaluated Hiberix for the booster dose in 1,008 children (*3,4*). The children in these studies received various Hib conjugate vaccines for the primary series, including Hiberix (not approved for primary series in the United States), and the monovalent Hib vaccines currently licensed for primary series in the United States, ActHIB (PRP-T, Sanofi Pasteur, Swiftwater, Pennsylvania) and PedvaxHIB (PRP-OMP, Merck & Co., Inc., West Point, Pennsylvania). In the seven core studies, Hiberix was given concomitantly with one of the following vaccines (all non-U.S. formulations, not licensed in the United States; GlaxoSmithKline Biologicals): diphtheria, tetanus, and acellular pertussis vaccine (DTaP), DTaP-hepatitis B vaccine (DTaP-HBV), DTaP-HBV-inactivated polio vaccine (DTaP-HBV), or DTaP-inactivated polio vaccine (DTaP-IPV). Serologic endpoints showed that the booster dose of Hiberix provided levels of antibodies protective against Hib invasive disease. Rates of adverse events generally were comparable to those observed with other childhood vaccines. In one of the core studies with 371 children, the frequencies of solicited local symptoms (i.e., redness, pain, or swelling) were each less than 25% (3), comparable to that reported in studies of currently licensed monovalent Hib conjugate vaccines (1). Hiberix was first introduced to markets outside the United States in 1996 and is used in nearly 100 countries (3,4).

Hiberix is supplied as a lyophilized powder for reconstitution in sterile 0.9% saline solution (3). Each 0.5 mL intramuscular dose of Hiberix contains 10  $\mu$ g of purified *H. influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conjugated to inactivated tetanus toxoid (PRP-T) (3). Hiberix does not contain thimerosal (3).

# **Indications and Guidance for Use**

Hiberix is licensed for use as the booster (final) dose for Hib vaccination for children aged 15 months through 4 years (before the 5th birthday) who have received a primary Hib vaccination series of 2 or 3 doses (depending on the formulation of the primary series vaccines). ACIP recommends Hib booster dosing at ages 12 through 15 months (1). To facilitate timely booster vaccination, Hiberix and other Hib conjugate vaccines can be administered as early as age 12 months, in accordance with Hib vaccination schedules for routine and catch-up immunization (5). Hiberix is not licensed for the primary Hib vaccination series; however, if Hiberix is administered inadvertently during the primary vaccination series, the dose should be counted as a valid PRP-T dose that does not need to be repeated if it was administered according to schedule (5). In these children, a total of 3 doses will complete the routine primary series.

Children aged 12 months through 4 years (before the fifth birthday) who did not receive a booster because of the recent shortage of Hib vaccines should receive a booster with any of the available Hib-containing vaccines at the earliest opportunity (2). With licensure of Hiberix and anticipated distribution, the increased supply of Hib-containing vaccines will be sufficient to support a provider-initiated notification process to contact all children whose Hib booster dose had been deferred. When feasible and when vaccine supply in the office is sufficient, vaccination providers should review electronic or paper medical records or immunization information system (e.g., registry) records to identify and recall children in need of a booster dose. If supplies are not adequate, providers should continue to follow previous recommendations to provide the booster dose at the child's next regularly scheduled visit (2).

# Information Regarding Supply of Hiberix, ActHib, and Pentacel

At this time, production of Merck Hib vaccine products remains suspended; however, supplies of Sanofi Pasteur vaccines ActHIB (monovalent Hib vaccine) and Pentacel (DTaP-IPV/Hib) are available for use for the primary Hib vaccination series and booster in infants and children. Vaccination providers with questions about supplies of Hiberix monovalent Hib vaccine purchased with nonpublic funds should contact GlaxoSmithKline Biologicals' customer service department (telephone, 866-475-8222). Providers with questions about supplies of ActHIB or Pentacel purchased with nonpublic funds should contact Sanofi Pasteur's customer service department (telephone, 800-822-2463). For public vaccine supplies, including Vaccines for Children Program vaccine, providers should contact their state/local immunization program to obtain vaccine. Providers ordering Hiberix through the Vaccines for Children Program may place orders in early October.

This recommendation reflects CDC's assessment of the existing national Hib vaccine supply and will be updated if the supply changes. Updated information about the national Hib vaccine supply is available at http://www.cdc.gov/vaccines/vac-gen/shortages/default.htm. Details about the routine Hib vaccination schedule are available at http://www.cdc.gov/vaccines/recs/schedules/default.htm#child. Adverse events after receipt of any vaccine should be reported to the Vaccine Adverse Event Reporting System at http://vaers.hhs.gov.

# References

- CDC. Recommendations for use of *Haemophilus* b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and *Haemophilus* b vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1993;42(No. RR-13).
- 2. CDC. Updated recommendations for use of *Haemophilus influenzae* type b (Hib) vaccine: reinstatement of the booster dose at ages 12–15 months. MMWR 2009;58:673–4.
- Food and Drug Administration. Product approval information: package insert. Hiberix (*Haemophilus* b conjugate [tetanus toxoid conjugate] vaccine). Available at http://www.fda.gov/downloads/biologicsblood vaccines/vaccines/approvedproducts/ucm179530.pdf.
- 4. Food and Drug Administration. Accelerated approval of Hiberix to help sustain adequate vaccine supply vaccine approved as a Hib booster dose. Available at http://www.fda.gov/newsevents/newsroom/press announcements/ucm179533.htm.
- CDC. Immunization schedules. Childhood schedule (birth to 6 years old). Available at http://www.cdc.gov/vaccines/recs/schedules/default. htm#child.

# Update: Influenza Activity – United States, April–August 2009

On September 10, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).

The first 2009 pandemic influenza A (H1N1) virus infections were identified in the United States in April 2009 (1). By August, the cumulative number of infections in the United States was estimated to be at least 1 million.* This report provides an overview of influenza activity during April-August 2009 and recommendations for the upcoming 2009-10 influenza season. Pandemic H1N1 influenza activity peaked in the United States during May and June and declined during July and early August. However, levels of influenza activity remained above normal for summer months, and focal outbreaks were reported throughout the summer. During the last 2 weeks of August, pandemic H1N1 influenza activity increased in certain areas of the United States. Clinicians and public health officials should be aware that these recent increases might signal an early start to the 2009–10 influenza season, with pandemic H1N1 influenza viruses predominating at least initially.

In the United States, CDC's National Influenza Surveillance System consists of nine different systems that monitor influenza viruses and the geographic spread and level of influenza activity. In addition to these ongoing systems, in April 2009, in response to the emergence and spread of the pandemic H1N1 virus, the states and CDC implemented line-listed reporting for cases of pandemic H1N1. In May, this system transitioned to include aggregate counts of pandemic H1N1 influenza cases, hospitalizations, and deaths. On July 24, CDC recommended that states discontinue reporting of individual confirmed and probable cases of pandemic H1N1 virus infection but to continue to provide aggregate reports of influenza-associated hospitalizations and deaths. From mid-April to August 30, a total of 9,079 hospitalizations and 593 deaths associated with laboratory-confirmed 2009 pandemic influenza A (H1N1) virus infections were reported to CDC.

World Health Organization and National Respiratory and Enteric Virus Surveillance System collaborating laboratories located in all 50 states and the District of Columbia report to CDC the number of respiratory specimens tested for influenza and the number positive by influenza type and subtype. Since May 3, the majority of influenza viruses identified have been pandemic H1N1 influenza A viruses. As of September 4, all of the influenza A H1N1 viruses characterized at CDC have been related antigenically to the reference strain chosen for the influenza A (H1N1) monovalent vaccine: A/California/7/2009(H1N1)pdm. Of 1,372 pandemic H1N1

^{*} Additional information available at http://www.cdc.gov/h1n1flu/surveillanceqa. htm.




FIGURE 1. Percentage of visits for influenza-like illness (ILI) reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), by surveillance week — United States, 2008–09, 2007–08, and 2006–06 influenza seasons

* The national baseline is the mean percentage of visits for ILI during noninfluenza weeks for the previous three seasons plus two standard deviations. A noninfluenza week is a week during which <10% of specimens tested positive for influenza. Use of the national baseline for regional data is not appropriate.

viruses tested for antiviral resistance at CDC from ill persons in the United States, 1,364 (99.4%) have been susceptible to oseltamivir. All eight pandemic H1N1 viruses found to be resistant to oseltamivir were obtained from persons taking oseltamivir for treatment or prophylaxis at the time of specimen collection. All viruses tested have been susceptible to zanamivir, and all have been resistant to amantadine and rimantadine.


Outpatient visits to health-care providers for influenzalike illness (ILI) are monitored in the United States through the Outpatient Influenza-like Illness Surveillance Network (ILINet). Visits to health-care providers were highest in February during the 2008–09 influenza season, but rose again in May 2009 after the 2009 H1N1 virus emerged (Figure 1). Visits to health-care providers for ILI were higher than usual in the summer and increased during the last 2 weeks of August. During that period, the proportion of outpatient visits for ILI in Department of Health and Human Services Region IV (Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee) increased to a level usually seen only during peak winter periods.

Laboratory-confirmed influenza-associated hospitalizations are monitored in two population-based surveillance networks: the New Vaccine Surveillance Network and the Emerging Infections Program. Total influenza hospitalization rates by age group for adults and children during April–August generally were similar to or lower than seasonal influenza hospitalization rates but were higher than usual for that period. (Figure 2).

Data from the 122 Cities Mortality Reporting System indicate that the proportion of deaths attributed to pneumonia and influenza was within the bounds of what is expected in the summer and did not exceed the epidemic threshold for 2 or more consecutive weeks at any time during April–August. However, 47 pediatric deaths associated with laboratory-confirmed pandemic H1N1 influenza occurred during April 26–August 29 and were reported to CDC.


Six states (Alabama, Alaska, Florida, Georgia, Mississippi, and South Carolina) and Puerto Rico reported widespread influenza activity for the most recent reporting week (August 23–29) (Figure 3). Any widespread influenza activity in August is uncommon. Thirteen additional states reported regional influenza activity.

**Reported by:** L Finelli, DrPH, L Brammer, MPH, L Blanton, MPH, S Epperson, MPH, R Dhara, MPH, A Fowlkes, MPH, D Mustaquim, MPH, L Kamimoto, MD, K Kniss, MPH, A Klimov, PhD, L Gubareva, PhD, A Fry, MD, A Fiore, MD, D Jernigan, MD, J Bresee, MD, Influenza Div; D Swerdlow, MD, National Center for Immunization and Respiratory Diseases, CDC. FIGURE 2. Laboratory-confirmed influenza hospitalization rates per 10,000 population, by age group and surveillance week — Emerging Infections Program, United States, April– August 2009



* Age group-specific average influenza rate, October-April, 2005-06, 2006-07, and 2007-08 influenza seasons.

FIGURE 3. Estimated influenza activity levels reported by state epidemiologists, by level of activity — United States, week ending August 29, 2009



* Levels of activity are 1) no activity; 2) sporadic: isolated laboratory-confirmed influenza cases or a laboratory-confirmed outbreak in one institution, with no increase in activity; 3) *local*: increased influenza-like illness (ILI), or at least two institutional outbreaks (ILI or laboratory-confirmed influenza) in one region with recent laboratory evidence of influenza in that region (virus activity no greater than sporadic in other regions); 4) *regional*: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least two but less than half of the regions in the state with recent laboratory evidence of influenza in those regions; and 5) *widespread*: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state with recent laboratory evidence of influenza in those regions; and 5) *widespread*: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state with recent laboratory evidence of influenza in those regions; and 5) *widespread*: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state with recent laboratory evidence of influenza in those regions; and 5) *widespread*: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state.

Editorial Note: Influenza activity during April-August 2009 was higher than expected for this period in all surveillance systems except for the 122 Cities Mortality Reporting System, and 2009 pandemic influenza A (H1N1) virus has continued to circulate as the predominant influenza virus. During the last 2 weeks of August, influenza activity increased in the southeastern United States to levels of ILI usually seen during winter seasonal influenza peaks. This increase might signal that other areas of the country also will have early influenza activity during the 2009-10 influenza season. Physicians, businesses, schools, and others are reminded that the timing and severity of influenza activity can be unpredictable, but that increased influenza activity resulting from pandemic H1N1, in addition to the usual seasonal influenza viruses, is expected this season. Changes in geographic spread of the virus will be monitored and reported weekly in the online FluView report.[†] Regular updates will be published in MMWR during the season as well. Additional guidance for this influenza season also is available online.§

[†] Available at http://www.cdc.gov/flu/weekly.

[§] Available at http://www.cdc.gov/h1n1flu.

CDC recently issued updated guidance to schools, universities, child care and early education programs, and businesses regarding methods to limit the spread of influenza in each of these settings (2–4). These guidance documents stress actions that will limit exposure to potentially infectious persons, such as the recommendation to stay home when ill and the separation of ill persons from well persons. CDC also updated recommendations for the amount of time a person with ILI should remain at home and away from school and work (5). CDC currently recommends that persons with ILI stay home for 24 hours after they are free from fever (100°F[37.8°C]) without taking fever-reducing medications. In addition, strict adherence to respiratory etiquette and hand hygiene should be stressed in school and work settings and in other settings where close contact between persons can occur.

Updated guidance on the use of influenza antiviral medications was issued by CDC on September 8 (6). Early treatment of all persons with severe illness from suspected or confirmed influenza, including those who are hospitalized, is recommended. In addition, this guidance recommends the early evaluation and treatment of persons with suspected influenza who are at greater risk for influenza-associated complications.⁹ However, most healthy children, adolescents, and adults with uncomplicated influenza-like illness do not require antiviral treatment. Approximately 97% of all influenza viruses currently circulating in the United States are pandemic H1N1 viruses that are sensitive to oseltamivir or zanamivir. Thus, CDC recommends either oseltamivir or zanamivir for treatment or chemoprophylaxis for influenza when use of antiviral medications is indicated. Clinical judgment always is an important component of treatment decision-making for persons who present with suspected influenza. When treatment is given, efforts to ensure that treatment is started as early as possible after symptom onset are critical.

The best means to prevent influenza illness is vaccination. CDC continues to recommend vaccination against seasonal influenza viruses, especially for all children, persons aged  $\geq$ 50 years, and persons at greater risk for influenza complications (7). Seasonal influenza vaccines are widely available now. Vaccines against the pandemic H1N1 influenza virus are expected to be available by mid-October and will be administered as separate vaccinations. The pandemic H1N1 monovalent vaccine is being prepared by the same manufacturers as the seasonal influenza vaccine. Many persons will be recommended to receive both the seasonal influenza vaccine

and the pandemic H1N1 vaccine. During the early phase of vaccine availability, the number of pandemic H1N1 vaccine doses will not be enough to vaccinate the entire U.S. population. The Advisory Committee on Immunization Safety has recommended that immunization programs focus initially on providing protection for persons who are at greater risk for infection or influenza complications, including pregnant women, household contacts and caregivers for children aged <6 months, health-care and emergency medical services personnel, all persons aged 6 months–24 years, and persons aged 25–64 years who have health conditions associated with greater risk for medical complications from influenza (*8*).

The Council of State and Territorial Epidemiologists and CDC have developed new case definitions for aggregate reporting of influenza-associated hospitalizations and deaths for the 2009–10 influenza season. These new case definitions will be implemented for the week ending September 5 (surveillance week 35). For aggregate reporting purposes, the 2008–09 influenza season was closed out on August 30; the total aggregate numbers of hospitalizations and deaths associated with pandemic H1N1 were reported on September 4. The first week of reporting influenza-associated hospitalizations and deaths for the 2009–10 season will include both seasonal and pandemic H1N1–associated hospitalizations and deaths, and will be reported on September 11.

#### References

- 1. CDC. Swine influenza A (H1N1) infection in two children—southern California, March–April 2009. MMWR 2009;58:400–2.
- 2. CDC. CDC guidance for state and local public health officials and school administrators for school (K-12) responses to influenza during the 2009–2010 school year. Atlanta, GA: CDC; August 31, 2009. Available at http://www.cdc.gov/h1n1flu/schools/schoolguidance.htm.
- CDC. CDC guidance for responses to influenza for institutions of higher education during the 2009–2010 academic year. Atlanta, GA: CDC; August 26, 2009. Available at http://www.cdc.gov/h1n1flu/institutions/ guidance.
- 4. CDC. CDC guidance on helping child care and early childhood programs respond to influenza during the 2009–2010 influenza season. Atlanta, GA: CDC; September 4, 2009. Available at http://www.cdc.gov/h1n1flu/ childcare/guidance.htm.
- 5. CDC. CDC recommendations for the amount of time persons with influenza-like illness should be away from others. Atlanta, GA: CDC; August 5, 2009. Available at http://www.cdc.gov/h1n1flu/guidance/exclusion.htm.
- CDC. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Atlanta, GA: CDC; September 8, 2009. Available at http://www. cdc.gov/h1n1flu/recommendations.htm.
- CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2009. MMWR 2009;58(No. RR-8).
- CDC. Novel H1N1 vaccination recommendations. Atlanta, GA: CDC; July 30, 2009. Available at http://www.cdc.gov/h1n1flu/vaccination/acip. htm.

⁹ Persons who are at greater risk for complications include 1) those aged <5 years (with highest risk among person age <2 years), 2) those aged >64 years, and, 3) those who have an underlying health condition (e.g., pregnancy or a chronic heart, lung, kidney, liver, metabolic, neurologic, or neuromuscular condition, or immunodeficiency).

# **QuickStats** FROM THE NATIONAL CENTER FOR HEALTH STATISTICS Percentage of Adults Aged ≥18 Years Who Have Ever Had An Oral Cancer Examination,* by Smoking Status and Age Group[†] — National Health Interview Survey, United States, 2008[§] 60 Current smoker 50 Former smoker Never smoker 40 Percentage 30 20 10 0 Total 18-39 <u>></u>40 Age group (yrs) * Based on affirmative responses to either of the following guestions: "Have you ever had an exam for oral cancer in which the doctor, dentist, or other health professional pulls on your tongue, sometimes with gauze wrapped around it, and feels under the tongue and inside the cheeks?" or "Have you ever had an exam for oral cancer in which the doctor, dentist, or other health professional feels vour neck?" [†] Based on responses to the following questions: "Have you smoked at least 100 cigarettes in your entire life?" and "Do you now smoke cigarettes every day, some days, or not at all?" Lifetime smoking status was defined as follows:

- 100 cigarettes in your entire life?" and "Do you now smoke cigarettes every day, some days, or not at all?" Lifetime smoking status was defined as follows: Never smoker (never smoked at all or smoked less than 100 cigarettes in lifetime); former smoker (smoked at least 100 cigarettes in lifetime but not currently smoking); and current smoker (smoked at least 100 cigarettes in lifetime and currently smoking).
- § Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population.
- ¶95% confidence interval.

In 2008, 29.4% of adults aged  $\geq$ 18 years had ever had an oral cancer examination in which a doctor, dentist, or other health professional pulled on their tongue or palpated their neck. Adults aged  $\geq$ 40 years were more likely to have ever had an examination than those aged 18–39 years, regardless of smoking status. Those most at risk for oral cancer (current smokers aged  $\geq$ 40 years) were less likely to have ever had an oral cancer examination than former smokers or never smokers.

SOURCE: National Health Interview Survey, 2008 data. Available at http://www.cdc.gov/nchs/nhis.htm.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending September 12, 2009 (36th week)*


	Current	Cum	5-year weekly			ases re evious	eported years	I	States reporting cases
Disease	week	2009	average [†]	2008	2007	2006	2005	2004	during current week (No.)
Anthrax	_	_	0	_	1	1	_	_	
Botulism:									
foodborne	—	12	1	17	32	20	19	16	
infant	—	33	2	109	85	97	85	87	
other (wound and unspecified)		17	1	19	27	48	31	30	
Brucellosis	2	67	2	80	131	121	120	114	CA (2)
Chancroid	2	20	0	25	23	33	17	30	NY (2)
Cholera	_	4	0	5	7	9	8	6	
Cyclosporiasis [§]	1	105	2	139	93	137	543	160	FL (1)
Diphtheria Domestic arboviral diseases ^{§,¶} :	_		_					_	
California serogroup	_	16	5	62	55	67	80	112	
eastern equine	_	3	1	4	4	8	21	6	
Powassan	_	1	Ö	2	7	1	1	1	
St. Louis	_	7	1	13	9	10	13	12	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis [§] ,**:									
Ehrlichia chaffeensis	4	489	19	1,137	828	578	506	338	NY (2), DE (1), TN (1)
Ehrlichia ewingii	—	4	0	9	_	_	_	_	
Anaplasma phagocytophilum	5	355	17	1,026	834	646	786	537	NY (5)
undetermined	—	79	4	180	337	231	112	59	
Haemophilus influenzae, ^{††}									
invasive disease (age <5 yrs):			-				_		
serotype b		16	0	30	22	29	9	19	<b>-</b> <i>i i i i</i>
nonserotype b	1	141	2	244	199	175	135	135	OK (1)
unknown serotype	_	170	2	163	180	179	217	177	
lansen disease§	_	45	2 1	80	101	66	87 26	105	
Hantavirus pulmonary syndrome [§]		6 100	8	18	32	40		24 200	NE(1) = (1) CA(1)
Hemolytic uremic syndrome, postdiarrheal [§] Hepatitis C viral, acute	3 7	128 1,363	8 14	330 878	292 845	288 766	221 652	200 720	NE (1), FL (1), CA (1) NY (1), MI (1), GA (1), FL (3), TX (1)
HIV infection, pediatric (age <13 years) ^{§§}	_	1,303	2	070	045	700	380	436	MT(1), MT(1), GA(1), TE(3), TA(1)
nfluenza-associated pediatric mortality [§] , ^{¶¶}	2	115	0	90	77	43	45	430	KS (1), TN (1)
Listeriosis	16	470	22	759	808	884	896	753	NY (4), PA (1), OH (1), MI (1), MN (1), MO (1),
Measles***	_	55	1	140	43	55	66	37	MD (1), VA (1), SC (1), FL (2), AR (1), CA (1)
Meningococcal disease, invasive ^{†††} :		00		110	10	00	00	01	
A, C, Y, and W-135	_	185	4	330	325	318	297	_	
serogroup B	_	96	2	188	167	193	156	_	
other serogroup	1	19	0	38	35	32	27	_	CO (1)
unknown serogroup	4	324	9	616	550	651	765	_	NY (1), MD (1), CA (2)
Mumps	4	263	13	454	800	6,584	314	258	SC (1), FL (2), NV (1)
Novel influenza A virus infections	—	§§§	0	2	4	N	N	Ν	
Plague	_	6	0	3	7	17	8	3	
Poliomyelitis, paralytic	—	_	—	—	_	—	1	—	
Polio virus infection, nonparalytic§	—	_	_	_		N	N	N	
	_	_7	0	8	12	21	16	12	
Q fever total [§] , ^{¶¶¶} :	1	57	3	124	171	169	136	70	
acute	1	48	1	110	_	_	_	—	MO (1)
chronic	_	9	0	14	_	_	_		
Rabies, human	_	1 4	0	2	1	3	2	7	
Rubella**** Rubella, congenital syndrome	_	4	U	16	12	11	11	10	
SARS-CoV [§] , ^{††††}	_		_	_	_		_'	_	
Smallpox [§]	_	_	_	_	_	_	_	_	
Streptococcal toxic-shock syndrome [§]	_	99	1	157	132	125	129	132	
Syphilis, congenital (age <1 yr)	_	121	8	434	430	349	329	353	
etanus	1	7	1	19	28	41	27	34	MO (1)
oxic-shock syndrome (staphylococcal)§	_	55	2	71	92	101	90	95	
Trichinellosis	_	12	0	39	5	15	16	5	
ularemia	_	47	3	123	137	95	154	134	
Typhoid fever	5	244	12	449	434	353	324	322	CT (1), MD (1), FL (2), CA (1)
ancomycin-intermediate Staphylococcus aureus	[;] 1	52	1	63	37	6	2	_	PA (1)
/ancomycin-resistant Staphylococcus aureus§	—	_	—	_	2	1	3	1	
/ibriosis (noncholera Vibrio species infections)§	13	338	12	492	549	N	N	N	MD (2), VA (1), FL (2), WA (3), CA (5)
fellow fever	_	_	_	_	_	_	_	_	

See Table I footnotes on next page.

#### TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending September 12, 2009 (36th week)*


- -: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts.
- * Incidence data for reporting year 2008 and 2009 are provisional, whereas data for 2004, 2005, 2006, and 2007 are finalized.
- [†] Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
  [§] Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and information arboviral diseases. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
- influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¹ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- ⁺⁺ Data for *H. influenzae* (all ages, all serotypes) are available in Table II.
- ^{§§} Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- ¹¹¹ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. A total of 113 influenza-associated pediatric deaths occurring during the 2008–09 influenza season have been reported. One influenza-associated pediatric death occurring during the 2009–10 influenza season beginning September 1, 2009, has been reported.
- *** No measles cases were reported for the current week.
- ttt Data for meningococcal disease (all serogroups) are available in Table II.
- §§§ CDC discontinued reporting of individual confirmed and probable cases of novel influenza A (H1N1) viruses infections on July 24, 2009. CDC will report the total number of novel influenza A (H1N1) hospitalizations and deaths weekly on the CDC H1N1 influenza website (http://www.cdc.gov/h1n1flu).
- In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.
- **** No rubella cases were reported for the current week.
- titt Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

# FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals September 12, 2009, with historical data



* No measles cases were reported for the current 4-week period yielding a ratio for week 36 of zero (0).

[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.



(36th week)*			Chlamyd	ia [†]			Coccid	iodomy	cosis			Crvr	otosporid	iosis	
		Prev					Previ						ious		
	Current	52 w	eeks	Cum	Cum	Current	52 we	eks	Cum	Cum	Current	52 v	veek	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	9,302 661	22,513 766	25,700 1,655	770,096 27,870	811,453 25.465	175	160 0	472 1	7,643	4,444 1	101 3	124 5	401 30	4,298 238	5,185 303
New England Connecticut	169	222	1,000	27,870 7,978	25,465 7,349	N	0	0	1 N	N	- 3	5 0	23	238	303 41
Maine [§] Massachusetts	61 362	48 342	75 945	1,692 13,672	1,732 12,235	N N	0	0 0	N N	N N	2	0 2	5 13	22 111	31 126
New Hampshire	_	39	63	1,162	1,407	_	Ō	1	1	1		1	4	39	47
Rhode Island [§] Vermont [§]	69	66 22	244 53	2,576 790	1,939 803	N	0 0	0 0	N	N	1	0 1	3 5	4 39	7 51
Mid. Atlantic	2,150	2,926	6,734	106,134	100,782		0	0			7	13	30	502	507
New Jersey New York (Upstate)	260 523	415 580	838 4,563	14,296 21,266	15,437 18,506	N N	0 0	0 0	N N	N N	7	0 4	3 13	8 145	30 168
New York City	990 377	1,146	3,130	41,057	38,675	N	0	0	N	N	—	1 7	8	50	77
Pennsylvania E.N. Central	993	835 3,494	1,072 4,382	29,515 116,429	28,164 132,748	N 1	0	4	N 23	N 35	10	29	19 105	299 947	232 1,366
Illinois Indiana	279	1,088 428	1,367 713	35,040 16,206	40,147 14,903	N N	0	0	N N	N	_	2 3	11 17	93 129	138 128
Michigan	566	853	1,332	31,600	31,276	1	0	3	12	26	3	5	13	172	178
Ohio Wisconsin	41 107	761 346	1,300 494	21,800 11,783	31,656 14,766	N	0 0	2 0	11 N	9 N	7	9 8	59 40	285 268	391 531
W.N. Central	577	1,322 192	1,664	44,566	45,937 6.026	N	0	1 0	7 N	1 N	20	17	47	666 154	674 214
lowa Kansas	187 9	154	256 549	6,730 5,312	6,296	N	0	0	N	N	_	4 1	13 5	50	55
Minnesota Missouri	318	254 510	342 646	8,070 18,021	9,930 16,818	_	0 0	0 1	7	1	11 2	4 3	33 12	194 122	139 124
Nebraska§	63	105	219	3,688	3,657	N	0	0	N	N	7	2	5	71	79
North Dakota South Dakota	_	24 58	60 81	772 1,973	1,250 1,960	N N	0 0	0 0	N N	N N	_	0 2	10 6	7 68	2 61
S. Atlantic	1,272	4,107	5,453	134,459	165,931	—	0	1	5	3	25	21	49	710	615
Delaware District of Columbia	93 138	85 126	180 226	3,285 4,737	2,524 4,829	_	0 0	1 0	1	1	_	0 0	1 2	6 2	10 9
Florida Georgia	473 3	1,420 753	1,597 1,909	50,427 20,762	49,134 28,834	N N	0 0	0 0	N N	N N	23 1	8 6	35 23	270 257	270 164
Maryland§	119	426	772	14,450	16,080	—	0	1	4	2	1	1	5	30	28
North Carolina South Carolina [§]	_	0 534	1,193 1,422	16,540	22,885 18,073	N N	0 0	0 0	N N	N N	_	1	16 7	58 34	26 36
Virginia [§] West Virginia	446	618 68	926 101	21,815 2,443	21,370 2,202	N N	0 0	0	N N	N N	_	1 0	6 2	43 10	53 19
E.S. Central	1,160	1,751	2,209	63,042	57,814	_	0	0	_	_	2	3	10	132	110
Alabama ^ş Kentucky	134	475 256	624 458	15,693 9,190	17,403 8,099	N N	0 0	0 0	N N	N N	_	1	4 4	37 39	50 23
Mississippi	490	454	841	16,941	13,568	Ν	0	0	N	Ν	_	0	3	10	12
Tennessee [§] W.S. Central	536 284	580 2,883	809 5,300	21,218 100,641	18,744 102,269	N	0	0 1	N 1	N 3	2 15	1 11	5 271	46 324	25 907
Arkansas§	7	273	418	9,737	9,893	Ν	Ō	Ó	Ň	N	_	1	10	32	47
Louisiana Oklahoma	261 16	420 178	1,134 2,735	14,718 9,589	14,642 9,185	N	0 0	1 0	1 N	3 N	5	1 2	6 16	29 85	42 63
Texas [§] Mountain		1,967 1,465	2,520 2,145	66,597 49,220	68,549 50,954	N 126	0 110	0 369	N 5,925	N 3,011	10 5	7 9	258 22	178 329	755 422
Arizona	22	460	735	15,717	16,986	122	108	365	5,853	2,933	_	1	4	25	63
Colorado Idaho§	189 64	390 68	728 313	12,261 2,437	12,022 2,716	N N	0 0	0	N N	N N	1 3	2 1	10 7	104 57	80 44
Montana [§] Nevada [§]	126	54 167	88 455	1,903 6,929	2,109 6,732	N 4	0 1	0 3	N 44	N 43	_	0 0	4 4	27 14	38 11
New Mexico§	50	176	540	5,958	5,290	4	Ó	2	8	23	1	2	10	74	141
Utah Wyoming§	_	99 34	251 97	2,679 1,336	4,082 1,017	_	0 0	2 1	20	10 2	_	0 0	3 2	13 15	30 15
Pacific	1,754	3,645	4,689	127,735	129,553	48	41	172	1,681	1,390	14	11	24	450	281
Alaska California	1,213	96 2,817	199 3,599	3,128 99,468	3,225 100,673	N 48	0 41	0 172	N 1,681	N 1,390	12	0 6	1 20	5 269	3 163
Hawaii Oregon§	375	119 198	247 631	4,050 6,683	3,972 6,924	N	0	0 0	N	N N	1	0 3	1 8	1 122	2 51
Washington	166	414	571	14,406	6,924 14,759	N	0	0	N	N	1	1	8 6	53	62
American Samoa C.N.M.I.	_	0		_	73	<u>N</u>	0	0	<u>N</u>	N	<u>N</u>	0	0	<u>N</u>	<u>N</u>
Guam Puerto Rico	_	2 130	8 332	5,076	107 5,010	N	0 0	0 0	N	N	N	0 0	0 0	N	N
U.S. Virgin Islands	_	9	17	290	478	_	0	0		_	_	0	0	_	_

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardias	is				Gonorrhe	a		Ha		s <i>influenz</i> s, all sero		ve
		Prev	rious reeks					vious veeks					/ious /eeks		
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008
United States	235	320	641	11,353	11,945	2,130	5,318	7,164	181,989	229,250	20	60	124	2,147	2,001
New England Connecticut	12	28 5	55 14	943 162	1,090 230	96 48	94 45	301 275	3,345 1,534	3,586 1,682	1	3 0	16 12	140 42	116 27
Maine [§]	_	4	12	127	112	6	2	9	96	63	—	0	2	14	9
Massachusetts New Hampshire	10	12 2	31 10	429 104	463 110	29	39 2	112 6	1,374 70	1,513 73	1	2 0	5 2	71 7	57 9
Rhode Island§	_	1	8	35	61	13	6	19	241	228	_	0	7	3	6
Vermont [§]	2	3	15	86	114		1	4	30	27	_	0	1	3	8
Mid. Atlantic New Jersey	49	63 7	116 17	2,130 215	2,175 358	452 66	592 87	1,138 123	21,269 2,991	22,425 3,695	3	12 2	25 7	437 84	370 63
New York (Upstate) New York City	36 2	25 16	81 30	851 519	720 573	96 197	109 210	664 577	3,950 7,647	4,138 7,059	_	3 2	20 11	103 84	107 64
Pennsylvania	11	16	46	545	524	93	190	267	6,681	7,533	3	4	10	166	136
E.N. Central	27	44	80	1,492	1,817	307	1,080	1,627	35,965	47,492	6	12	28	472	322
Illinois Indiana	N	9 0	23 11	272 N	501 N	106	332 149	494 252	10,750 5,257	14,000 6,039	_	3 1	9 22	117 50	102 56
Michigan	7	12	22	406	387	145	281	493	10,174	11,645	_	0	3	16	17
Ohio Wisconsin	20	16 8	27 19	553 261	583 346	30 26	245 93	455 140	6,793 2,991	11,426 4,382	3 3	2 3	6 20	76 213	99 48
W.N. Central	20	25	143	1,042	1,304	112	283	393	9,592	11,600	_	3	15	112	148
lowa Kansas	6	6 2	18 7	213 70	208 110	22 5	34 36	53 83	1,137 1,360	1,050 1,532	_	0	0 2	11	2 17
Minnesota		0	106	250	403	_	43	65	1,328	2,171	_	0	10	40	46
Missouri Nebraska [§]	10 4	7 3	28 9	332 118	341 140	68 17	129 23	183 54	4,539 942	5,549 994	_	1 0	4	37 19	53 21
North Dakota	—	0	16	9	10	_	2	7	43	79	—	0	4	5	9
South Dakota S. Atlantic		1 70	7 109	50 2,533	92 1,918	380	7 1,168	20 2,042	243 38.601	225 58,253	7	0 13	0 31		 510
Delaware	_	Ō	3	[′] 18	28	24	16	37	655	770	_	0	1	3	6
District of Columbia Florida	31	0 37	5 59	16 1,318	46 795	37 187	51 421	88 486	1,870 14,661	1,773 16,439	4	0 4	2 10	178	5 132
Georgia	1	13	67	661	475	1	251	876	7,056	10,692	2	3	9	115	104
Maryland [§] North Carolina	7 N	5 0	9 0	170 N	184 N	24	121 0	212 470	3,845	4,260 10,072	1	1 1	6 17	65 57	74 54
South Carolina [§] Virginia [§]	5 3	2 8	8 31	67 251	81 257	107	170 150	413 308	5,234 4,928	6,588 7,131	_	1 1	5 6	37 42	47 70
West Virginia	_	0 1	3	32	52	107	11	23	4,928	528	_	0	3	42 25	18
E.S. Central	3	7	20	238	317	364	514	714	18,160	20,939	1	3	9	119	107
Alabama ^ş Kentucky	N	3 0	12 0	111 N	182 N	37	142 86	216 135	4,432 2,668	6,856 3,172	_	0 0	4 5	26 18	16 6
Mississippi	N	0 4	0	N	N	167	143	252	5,302	4,951	1	0	1	4 71	11
Tennessee [§] W.S. Central	3 8	4 9	13 22	127 306	135 284	160 100	162 865	273 1,383	5,758 29,334	5,960 35,156	1	2 2	6 22	80	74 90
Arkansas§	3	2	8	94	94	1	83	134	3,001	3,230	—	0	2	13	11
Louisiana Oklahoma	5	3 4	8 18	96 116	101 89	83 16	146 70	420 613	4,745 3,348	6,345 3,371	1	0 1	1 20	12 54	8 64
Texas§	Ň	0	0	N	N	_	551	725	18,240	22,210	_	Ó	1	1	7
Mountain Arizona	20	27 3	59 10	933 135	1,060 89	45 1	175 54	313 88	5,780 1,785	8,027 2,394	1	5 1	11 7	173 60	226 88
Colorado	14	9	27	342	362	—	56	152	1,697	2,439	1	1	6	54	42
Idaho [§] Montana [§]	6	3 2	10 10	122 71	132 61	3	2 1	13 6	70 48	124 78	_	0 0	1	4	12 3
Nevada§	_	2	10	75	78	19	30	91	1,233	1,586	_	0	2	14	14
New Mexico [§] Utah	_	1 4	7 15	66 91	83 225	22	24 4	52 15	769 126	960 357	_	0 0	3 2	17 20	34 30
Wyoming§	—	1	4	31	30	—	1	7	52	89	—	0	1	3	3
Pacific Alaska	49	51 2	130 10	1,736 67	1,980 61	274	550 15	765 24	19,943 528	21,772 361	_	2 0	8 3	92 13	112 16
California	29	34	57	1,171	1,316	249	468	658	16,766	17,866	—	0	3	22	38
Hawaii Oregon [§]	9	0 7	2 17	9 241	33 318	16	12 20	21 48	425 698	432 844	_	0 1	3 3	22 32	14 42
Washington	11	7	74	248	252	9	46	80	1,526	2,269	—	0	2	3	2
American Samoa C.N.M.I.	_	0	0	_	_	_	0	0	_	3	_	0	0	_	_
Guam	_	0	0	_	_	_	1	15	_	45	_	0	0	_	
Puerto Rico U.S. Virgin Islands	_	2 0	15 0	63	147	_	4 2	24 7	166 80	200 92	N	0 0	1 0	3 N	1 N
0.0. Virgin Islanus		0					۷	/		32	11	0	0	11	11

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Met * Incidence data for reporting year 2008 and 2009 are provisional. † Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

# **MMWR**

(Soln week)				Hepat	itis (viral,	acute), by	type†						,		
			Α					В					gionellosi	is	
	Current		vious veeks	Cum	Cum	Current		/ious /eeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	17	36	89	1,266	1,856	23	65	197	2,125	2,602	41	51	122	1,903	2,011
New England Connecticut	1	2 0	8 4	65 17	91 18	_	1 0	4 3	27 10	58 23	2 2	3 1	18 5	102 42	137 27
Maine [§] Massachusetts	_	0 1	5 3	1 39	5 46	_	0 0	2 2	8 6	10 14	_	0 1	2 6	4 40	6 58
New Hampshire	—	0	1	3	10	_	0	2 0	3	5	—	0	2	8	24
Rhode Island [§] Vermont [§]	_	0 0	2 1	3 2	10 2	_	0 0	1	_	4 2	_	0 0	14 1	4	17 5
Mid. Atlantic New Jersev	2	5	13 5	168 33	219 55	—	7	17 6	219 54	312 92	15	15 2	63 14	747 119	663 78
New York (Upstate)	1	1 1	4	37	44	_	1 1	11	38	43	11	5	29	245	207
New York City Pennsylvania	1	2 1	6 4	55 43	74 46	_	1 3	4 8	42 85	70 107	4	2 6	20 25	133 250	91 287
E.N. Central	_	5	17	175	252	_	8	21	265	356	12	9	29	338	439
Illinois Indiana	_	1 0	12 3	77 12	92 14	_	1	6 18	36 46	138 24	_	1	13 5	26 25	57 38
Michigan	_	1	5	47	92	_	2	8	92	98	2	2	10	82	125
Ohio Wisconsin	_	1 0	4 3	30 9	29 25	_	1 0	13 4	67 24	82 14	10	4 0	17 6	200 5	197 22
W.N. Central	—	2	16	87	205	2	3	16	117	57	—	2	7	65	92
lowa Kansas	_	1 0	2 1	25 7	98 13	_	0 0	3 2	23 5	14 6	_	0 0	2 1	16 3	13 1
Minnesota Missouri	_	0 0	12 3	14 20	26 25	1	0 1	11 5	20 55	7 24	_	0 1	3 5	8 28	9 51
Nebraska§	_	0	3	19	39	1	Ó	2	13	5	—	0	2	8	16
North Dakota South Dakota	_	0 0	2 1	2	4	_	0 0	1 1	1	1	_	0 0	3 1	1	2
S. Atlantic	9	7	14	281	274	13	18	32	626	630	8	9	22	323	322
Delaware District of Columbia	U	0 0	1 0	3 U	6 U	U U	0 0	1 0	U U	U U	_	0 0	5 2	11 4	9 12
Florida Georgia	5 1	4 1	8 3	132 44	103 39	10 3	6 3	11 9	213 101	220 120	4	3 1	7 5	114 33	96 26
Maryland§	2	Ö	4	28	33	_	1	5	47	57	2	2	10	77	93
North Carolina South Carolina§	_	0 0	4 3	25 27	48 9	_	2 1	19 4	130 31	51 51	_	0 0	7 1	39 5	16 8
Virginia [§] West Virginia	1	0 0	6 1	21 1	31 5	_	2 0	10 19	57 47	76 55	2	1 0	5 1	34 6	38 24
E.S. Central	_	1	5	30	58	1	7	11	209	269	_	2	11	82	87
Alabama [§] Kentucky	_	0 0	2	7 7	8 21	_	2 2	7 7	63 53	76 65	_	0 1	1 3	7 36	13 41
Mississippi	—	0	1	8	4	_	1	2	18	32	—	0	1	3	1
Tennessee [§] W.S. Central	_	0 3	2 43	8 103	25 177	1 3	2 10	6 99	75 332	96 516	_	1	8 21	36 44	32 58
Arkansas§	_	0	1	4	6	_	1	5	36	42	—	0	2	3	10
Louisiana Oklahoma	_	0 0	1 6	3 3	10 7	2	1 2	4 17	33 71	65 76	_	0 0	2 6	4 3	8 3
Texas§	_	3	37	93	154	1	6	76	192	333	_	1	19	34	37
Mountain Arizona	1	3 2	7 6	113 54	166 84	1	3 1	7 4	93 36	144 56	2 1	2 1	8 4	75 35	58 14
Colorado Idaho [§]	_	0 0	5 1	34 3	29 16	_	0 0	2 2	16 6	24 7	_	0 0	2 1	7	6 3
Montana§	_	0	1	5	1	_	0	0	—	2	_	0	2	4	4
Nevada [§] New Mexico [§]	1	0 0	3 1	7 6	7 15	1	0 0	3 2	22 5	30 8	1	0 0	2 2	10 2	8 5
Utah Wyoming§	_	0	1 0	4	11 3	_	0 0	1 2	5 3	12 5	_	0	4 1	15 1	18
Pacific	4	7	17	244	414	3	6	36	237	260	2	3	12	127	155
Alaska California	4	0 5	1 17	3 193	3 335	3	0 5	1 28	2 174	9 178	2	0 3	1 9	1 102	1 119
Hawaii	_	0	1	5	15	_	0	1	4	6	_	0	1	1	6
Oregon [§] Washington	_	0 1	2 4	12 31	23 38	_	0 1	4 8	26 31	32 35	_	0 0	2 4	8 15	14 15
American Samoa	—	0	0	_	_	_	0	0	—	_	Ν	0	0	Ν	Ν
C.N.M.I. Guam	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_
Puerto Rico		0 0	2 0	17	20	_	0 0	3 0	12	41	—	0 0	0 0	—	—
U.S. Virgin Islands		U	0				U	0				U	U		

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Data for acute hepatitis C, viral are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

1018

		L	yme disea	se				Malaria		Meningococcal disease, invasive [†] All groups					
	Previous 52 weeks							ious				Previous 52 weeks			
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	eeks Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008
United States	187	500	1,637	19,400	23,797	6	23	46	768	812	5	17	48	624	872
New England	2	103	327	3,347	8,936	_	1	5	30	43	—	0	4	21	23
Connecticut Maine [§]	_	0 9	105 73	467	3,086 312	_	0 0	4 1	5 1	10 1	_	0 0	1	2 3	1 4
Massachusetts	2	30	213	1,881	3,827	_	0	3	19	23 3	—	0	3 1	12	15
New Hampshire Rhode Island [§]	_	13 0	73 78	750 54	1,299 119	_	0	1	2 1	2	_	0 0	1	1 2	2 1
Vermont§	—	4	35	195	293	_	0	1	2	4	—	0	1	1	—
Mid. Atlantic New Jersey	115	247 35	1,401 264	11,621 2,629	9,529 2,837	_	5 0	17 3	175	219 54	1	2 0	5 2	71 8	96 13
New York (Upstate)	77	87	1,368	2,965	3,117	_	1	10	36	22	1	0	2	18	25
New York City Pennsylvania	38	3 53	33 608	92 5,935	584 2,991	_	3 1	11 4	103 36	116 27	_	0 1	2 4	12 33	19 39
E.N. Central	4	19	179	1,549	1,893	2	3	8	105	114	_	3	8	100	151
Illinois	_	1	10	80	<b>97</b>	—	1	4	46	61	—	1	6	26	54
Indiana Michigan	_	1	4 10	33 76	31 61	_	0 0	1 3	7 17	5 13	_	0 0	3 5	24 18	22 25
Ohio	1	1	3	33	33	2	1	6	31	22	_	0	3	26	32
Wisconsin	3	15	165	1,327	1,671	_	0	2	4	13	_	0	1	6	18
W.N. Central lowa	1	5 1	336 12	171 71	441 90	_	1 0	7 3	39 8	46 5	_	1 0	9 1	49 6	76 15
Kansas	—	0	4	15	6	—	0	2	3	4	—	0	2	7	4
Minnesota Missouri	_	0 0	326 2	67 4	330 4	_	0 0	7 2	13 9	19 10	_	0 0	4 3	10 18	21 23
Nebraska§	1	0	3	13	8	_	0	1	5	8	_	0	1	5	10
North Dakota South Dakota	_	0 0	10 1	1	3	_	0	0 1	1	_	_	0	3 1	1 2	1 2
S. Atlantic	59	63	207	2,476	2,767	1	6	17	237	204	1	2	9	114	122
Delaware District of Columbia	2	12 0	63 5	727	605 54	_	0 0	1 2	3 5	2 2	_	0 0	1 0	_2	1
Florida	8	1	9	55	45	_	2	7	69	36	_	1	4	42	42
Georgia Mandand [®]		0	6	39	31	-	1	5	51	46	_	0 0	2	21	14
Maryland [§] North Carolina	18	29 1	130 14	1,140 56	1,374 15	1	0	8 5	52 21	53 22	1	0	1 5	7 18	13 11
South Carolina [§] Virginia [§]	4	0 12	3 61	19 322	18 518	_	0	1 4	2 32	8 33	_	0 0	1 2	10 9	19 17
West Virginia	27	0	17	100	107	_	0	4	2	2	_	0	2	9 5	5
E.S. Central	1	0	2	19	39	1	0	3	24	13	_	0	3	21	39
Alabama [§] Kentucky	_	0 0	1	2 1	9 4	_	0 0	3 2	6 8	3 4	_	0	1	5 4	5 7
Mississippi	_	0	Ó	_	1	_	0	1	1	1	_	0	i	2	9
Tennessee§	1	0	2	16	25	1	0	3	9	5	_	0	1	10	18
W.S. Central Arkansas [§]	_	1 0	21 0	37	71	_	1 0	8 1	34 3	52	_	1 0	12 2	58 5	94 13
Louisiana	_	0	0	_	3	_	0	1	3	2	_	0	3	11	19
Oklahoma Texas [§]	_	0 1	2 21	37	68	_	0 1	2 7	2 26	2 48	_	0 1	3 9	6 36	12 50
Mountain	1	1	13	32	42	_	0	4	22	21	1	1	4	50	46
Arizona Colorado	1	0 0	2 1	3 4	7 3	_	0 0	2 3	6 8	10 3	1	0 0	2 2	13 16	6 9
Idaho§	_	0	2	9	6	_	0	1	0 1		—	Ō	1	5	9 4
Montana [§] Nevada [§]	—	0 0	13 2	2 12	4 10	—	0 0	3 1	4	4	_	0 0	2 2	4 4	4 7
New Mexico [§]	_	0	1	1	8	_	0	1	_	2	_	0	1	3	7
Utah Wyoming [§]	—	0 0	1		2 2	—	0 0	2 0	3	_2	—	0 0	1 2	1 4	7 2
Pacific	4	4	13	ı 148	2 79	2	3	10	102	100	2	3	2 14	4 140	2 225
Alaska	—	0	1	2	5	_	Ō	1	2	4	_	Ō	2	4	6
California Hawaii	2 N	3 0	12 0	127 N	41 N	2	2 0	8 1	77 1	72 2	_2	2 0	8 1	94 3	166 4
Oregon§	_	0	3	12	26	_	0	2	9	4	_	0	6	26	26
Washington	2	0	12	7	7	_	0	3	13	18	—	0	6	13	23
American Samoa C.N.M.I.	N	0	0	N	N	_	0	0	_	_	_	0	0	_	_
Guam Puerto Rico		0	0		_	_	0	2	_	1	_	0	0	_	_
	N	0	0	N	N	_	0	1	2	2	_	0	1	_	2

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(36th week)*			Pertussis				Ba	bies, anir	nal	Rocky Mountain spotted fever					
		Prev	/ious					vious					vious		
	Current	52 v	/eeks	Cum	Cum	Current	52 w	eeks	Cum	Cum	Current	52 w	eeks	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	97	273	1,697	8,953	6,262	32	69	138	2,514	3,013	6	32	179	1,029	1,654
New England Connecticut	3	14 0	27 4	428 26	712 40	1	8 3	14 10	225 101	282 138	_	0 0	2 0	9	4
Maine [†]	3	1 8	10 21	64 266	25 557	—	1 0	5 0	36	36	—	0 0	2	4	1
Massachusetts New Hampshire		0 1	21	200 53	22	_	0	7	24	29	_	0	0	4	1
Rhode Island [†] Vermont [†]	_	0 0	5 2	11 8	59 9		0 1	3 4	27 37	25 54	_	0 0	2 1	1	1
Mid. Atlantic	11	22	64	769	733	10	14	27	439	653	1	1	29	52	105
New Jersey	9	4 5	12 41	128 145	155 278	10	0	0 20	320	357	_	0	2 29	10	72
New York (Upstate) New York City	_	5 0	21	53	49		0	20	320	13	_	0	29 4	23	12 10
Pennsylvania	2	13	33	443	251	—	5	17	118	283	1	0	2	19	11
E.N. Central Illinois	25	54 11	238 45	1,841 284	1,029 206	4 3	2 1	19 9	185 77	195 81	_	1	6 6	60 37	124 91
Indiana	_	4	158	179	40	—	Ó	6	17	6	—	Ö	3	4	6
Michigan Ohio	7 18	11 20	27 57	480 792	167 517	1	1 0	5 7	50 41	64 44	_	0 0	2 4	5 14	3 24
Wisconsin	_	3	12	106	99	Ν	0	0	Ν	Ν	—	0	0	_	_
W.N. Central lowa	8	34 6	872 21	1,262 135	522 82	8	5 0	17 5	206 24	213 17	_2	4 0	25 2	223 4	360 7
Kansas	_	4	12	132	42	_	1	6	56	50	_	0	1	2	_
Minnesota Missouri	6	0 20	808 51	165 688	156 165	4 4	0 1	11 5	44 51	34 49	2	0 4	1 24	2 204	334
Nebraska [†]	2	4	32	110	54	—	0	2	_	29	—	0	2	11	16
North Dakota South Dakota	_	0 0	24 10	17 15	1 22	_	0 0	9 4	4 27	17 17	_	0 0	1 0	_	3
S. Atlantic	27	28	71	1,133	615	8	25	111	1,109	1,253	_	13	42	376	560
Delaware District of Columbia	_	0	2 2	10 2	11 3	_	0 0	0	_	_	_	0 0	3 0	15	26 6
Florida	18	8	32	410	189	_	0	95	123	138	_	0	2	5	9
Georgia Maryland [†]	_	3 3	11 9	106 78	62 84	7	0 6	71 14	262 264	279 323	_	1	6 3	37 27	66 69
North Carolina South Carolina [†]	1	0 4	65 17	204 171	79 85	N	2 0	4 0	N	N	_	7 0	36 9	225 16	245 30
Virginia [†]	8	3	24	128	95	_	10	23	375	446	_	2	9	47	101
West Virginia	_	0	5	24	7	1	2	6	85	67	_	0	1	4	8
E.S. Central Alabama [†]		15 4	33 19	568 216	220 30	_	2 0	7 0	70	135	_2	4 1	19 6	182 39	241 63
Kentucky Mississippi	_	6 1	15 4	178 41	59 77	_	1 0	4 2	36	33 2	_	0 0	1	1 7	1 10
Tennessee [†]	4	3	14	133	54	_	1	4	34	100	2	3	15	135	167
W.S. Central	4	55	389	1,779	995	_	0	13	45	75	1	1	161	106	224
Arkansas† Louisiana	3	4 2	38 8	171 90	64 63	_	0 0	5 0	23	41	_	0 0	61 1	47 2	44 5
Oklahoma Texas [†]	1	0 41	45 304	37 1,481	32 836	_	0 0	13 1	21 1	32 2	1	0	98 6	44 13	142 33
Mountain	8	17	31	594	602	_	1	9	57	67	_	1	3	10	33
Arizona	3	4	10	152	166	Ν	0	0 0	N	N	—	Ó	2 0	4	8
Colorado Idaho†	5	5 1	12 5	200 60	111 22	_	0	2	_	8	_	0 0	1	1	1
Montana [†] Nevada [†]	_	0 0	4 3	12 10	75 26	_	0	4 1	16 4	7 10	_	0 0	2 1	8 1	3 2
New Mexico [†]	_	1	10	39	32	_	0	2	16	23	—	0	1	1	4
Utah Wyoming [†]	_	3 0	19 5	113 8	159 11	_	0 0	6 4	4 17	7 12	_	0 0	1	1	5 9
Pacific	7	19	98	579	834	1	5	12	178	140	_	0	1	2	3
Alaska California	_	1 5	21 19	31 143	110 378	1	0 4	2 12	10 153	12 121	N	0	0	N 2	N
Hawaii	_	0	3	22	10	—	0	0	_	_	Ν	Õ	Ó	Ň	Ν
Oregon [†] Washington	7	3 6	16 76	183 200	125 211	_	0 0	3 0	15	7	_	0 0	0	_	3
American Samoa	_	0	0		_	Ν	0	0	Ν	Ν	Ν	0	0	Ν	Ν
C.N.M.I. Guam	_	0	0	_	_	_	0	0	_	_	N	0		N	N
Puerto Rico	_	0	1	1	_	—	1	3	27	46	Ν	0	0	N	Ν
U.S. Virgin Islands		0	0	_	_	N	0	0	N	N	N	0	0	N	N

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	Salmonellosis						ja toxin-pi	roducing	E. coli (S1	TEC)†	Shigellosis					
		Previous Curront 52 weeks Cum Cum						ious			Previous 52 weeks Cum Cum					
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	eeks Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	
United States	648	916	2,323	28,712	31,353	54	86	255	2,644	3,309	146	314	1,268	10,290	13,352	
New England	3	32 0	324 298	1,511 298	1,691 491	_	3 0	50 50	156 50	179 47	_	3 0	33 28	234 28	176 40	
Connecticut Maine [§]	_	2	7	83	104	_	0	3	14	13	_	0	1	2	18	
Massachusetts New Hampshire	3	23 3	39 42	805 198	848 107	_	1	6 3	58 23	85 14	_	3 0	27 3	183 8	101 4	
Rhode Island [§] Vermont [§]	—	2 1	11	87	73 68	_	0 0	1 6	 11	7	—	0 0	1 2	8 5	10	
Mid. Atlantic		91	5 182	40 3,102	3,956	5	7	о 18	237	13 341	10	56	2 79	э 1,955	3 1,690	
New Jersey New York (Upstate)	27	10 24	41 66	237 897	941 901	4	1 3	5 9	31 96	103 111	4	13 5	35 23	416 160	571 446	
New York City	2	19	49	776	886	_	1	5	39	36	1	9	23	294	539	
Pennsylvania E.N. Central	16 33	29 91	66 141	1,192 3,243	1,228 3,589	1 2	1 12	5 74	71 428	91 531	5 5	24 64	61 132	1,085 1,856	134 2,592	
Illinois		25	50	845	1,054	—	1	10	65	89	—	13	25	367	727	
Indiana Michigan	2	7 18	50 29	245 666	415 672	1	1 3	6 43	39 101	68 94	1	1 5	21 24	38 162	499 91	
Ohio Wisconsin	30 1	27 12	52 30	1,057 430	906 542	1	3 3	15 10	101 122	121 159	2 2	36 11	80 42	933 356	996 279	
W.N. Central	30	50	109	1,878	2,009	10	12	38	508	579	17	15	49	622	658	
lowa Kansas	2	7 6	15 19	301 225	315 327	1	2 1	14 7	122 30	150 31	_	2 3	12 11	47 147	117 28	
Minnesota Missouri	13 12	13 12	51 31	452 434	513 545	6 2	2 2	17 10	152 83	117 122	7 10	2 4	14 40	65 338	227 174	
Nebraska§	3	5	41	272	171	1	2	6	66	120	_	0	3	19	5	
North Dakota South Dakota	_	0 3	30 22	40 154	31 107	_	0 0	28 12	3 52	1 38	_	0 0	9 1	3 3	32 75	
S. Atlantic Delaware	255 1	262 2	440 8	7,798 72	7,622 110	10	13 0	30 2	433 11	588 10	18 3	47 1	85 8	1,593 75	2,225 7	
District of Columbia	_	0	5	20	49	_	0	1	1	5	_	0	2	6	16	
Florida Georgia	170 36	115 39	197 96	3,683 1,462	3,098 1,493	3 1	3 1	7 4	115 50	100 68	9 3	8 13	24 30	313 458	622 815	
Maryland§ North Carolina	16	15 23	26 104	502 778	592 755	3	1 2	8 21	60 74	95 65	2	6 6	14 27	257 251	69 112	
South Carolina§	20	15	54	496	703	_	0	3	21	32	1	3	14	86	431	
Virginia [§] West Virginia	11 1	21 4	88 23	626 159	671 151	2 1	2 0	16 3	82 19	181 32	_	5 0	59 3	141 6	125 28	
E.S. Central Alabama [§]	11	56 15	140 40	1,838 436	2,242 639	2	4 1	12 4	147 33	195 49	2	19 4	58 11	575 97	1,364 325	
Kentucky	_	10	18	335	308	_	2	7	52	63	_	2	25	143	209	
Mississippi Tennessee [§]	1 10	14 15	57 62	551 516	749 546	2	0 2	1 5	6 56	4 79	2	1 11	4 48	29 306	273 557	
W.S. Central	119	110	1,333 34	3,086	4,325	4	4	139	103	237	44	56 8	967	1,814	2,940	
Arkansas [§] Louisiana	9	12 16	43	411 599	508 754	1	0 0	5 1	26	37 7		4	20 17	236 108	388 498	
Oklahoma Texas [§]	18 92	14 56	102 1,204	440 1,636	508 2,555	2 1	1 2	82 55	21 56	22 171	11 31	5 42	61 889	197 1,273	93 1,961	
Mountain	29	57	113	1,980	2,322	1	10	40	319	387	17	25	54	816	658	
Arizona Colorado	12 14	20 13	48 34	705 471	727 515	1	1 3	4 18	55 104	50 106	13 3	17 2	41 11	611 67	320 75	
Idaho [§] Montana [§]	2	4 2	10 7	131 73	120 86	_	2 0	15 3	58 15	79 28	_	0 0	2 5	7 13	9 5	
Nevada§	1	4	13	180	162	_	Ō	4	20	13	1	1	11	48	153	
New Mexico [§] Utah	_	5 6	25 15	214 163	416 244	_	1	2 5	21 41	41 60	_	2 0	12 3	59 11	67 26	
Wyoming [§] Pacific		1 126	6 537	43 4,276	52 2 5 0 7		0 10	2 31	5 313	10 272	 33	0 27	1 82	 825	3	
Alaska	_	1	6	56	3,597 41	20	0	1	_	5	_	0	1	2	1,049	
California Hawaii	97 4	95 5	516 13	3,248 177	2,595 189	7	5 0	15 1	165 3	123 11	26 1	20 0	75 4	665 27	906 33	
Oregon [§] Washington	2 20	8 12	15 85	282 513	319 453	3 10	1 3	6 16	47 98	48 85	1 5	1 2	10 11	28 103	52 58	
American Samoa	_	0	1	_	2	_	0	0	_	_	_	0	2	3	1	
C.N.M.I. Guam	_	0	2	_	10	_	0	0	_	_	_	0	1	_	14	
Puerto Rico	2	8	40 0	249	484	_	0	1	1	—	_	0	2	7	22	
U.S. Virgin Islands	—	U	U	_	_		U	0	—	_	_	U	0	_	—	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. † Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

Durrent         S2 vecks         Cum         Cum         Cum         Durrent         B2 vecks         Cum         Cum         Cum         B2 vecks         Cum         Cum </th <th>(36th week)*</th> <th></th> <th>Strentococcal</th> <th>diseases inv</th> <th>asive group A</th> <th></th> <th colspan="8">Streptococcus pneumoniae, invasive disease, nondrug resistant[†] Age &lt;5 years</th>	(36th week)*		Strentococcal	diseases inv	asive group A		Streptococcus pneumoniae, invasive disease, nondrug resistant [†] Age <5 years							
Percenting uses         Week         Meet         Name         Colors         Week         Meet         Meet         Mode         2009         2008           New England         -         5         23         3.975         4.142         14         36         122         1.101         1.238           New England         -         0         2         13         200         -         0         1         1         3         1           Maine ⁶ -         0         2         13         200         -         0         1         3         1         6           Weenhampative         -         0         2         9         21         -         0         1         2         -         7         7         N         5         68         99         1         5         3         181         15         -         -         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1 <th></th> <th></th> <th>•</th> <th>-</th> <th>asive, group A</th> <th></th> <th></th> <th>Prev</th> <th></th> <th></th> <th></th>			•	-	asive, group A			Prev						
United States         27         101         239         3,875         4,142         14         36         122         1,191         1,238           Connesticut         —         0         28         229         299         299         290         —         1         1         43         690           Connesticut         —         0         2         13         20         —         0         1         3         1           Massediments         —         0         0         14         40         —         0         2         —         0         1         2         —         7           Mediastande         —         0         3         13         122         —         0         1         2         —         7           Vermonit         —         0         3         13         122         —         0         1         2         —         7         7         1         0         3         13         155         7         1         0         31         85         39         99         99         10         1         13         26         26         26         59         99	Reporting area													
New Enginat         -         5         28         229         200         -         1         12         43         60           Mains ⁶ -         0         1         3         1         -         -         0         1         3         1           Mains ⁶ -         0         1         4         38         1         1         -         0         1         3         1           Mains ⁶ -         0         2         9         21         -         0         1         2         -         7           Wite Mainteinte         3         19         43         784         850         -         1         5         33         181         155         460         -         1         1         65         39         9         21         1         0         31         65         39         9         1         6         1         5         68         36         36         38         31         101         10         10         10         10         10         10         10         10         10         10         10         10         10         10														
$\begin{array}{c} \mbox{Conscription} & - & 0 & 21 & 63 & 86 & - & 0 & 11 & - & - & - & - & - & - & - & - & $														
	Connecticut		0	21	63	86		Ó		_	_			
New Hampshie         -         1         4         34         20         -         0         2         8         8           Vernomit         -         0         2         9         21         -         0         1         2         7           Vernomit         -         0         3         13         12         -         0         1         2         7         -           Mick Attentic         3         16         9         16         16         16         16         86         39           New York (Upstate)         -         -         6         18         270         1         6         18         286         39         28         39         21         -         1         6         30         28         28         30         31         11         100         13         26         28         30         31         31         120         116         13         34         36         36         39         31         -         1         4         30         37         32         N         0         1         N         N         N         N         N         N         N											•			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		_												
Mid. Attantic         3         19         43         764         650         1         5         33         181         155           New York (Upstele)         3         7         25         261         265         -         2         17         85         69           New York (Upstele)         3         7         25         261         265         -         2         17         85         69           New York (Upstele)         3         7         42         275         277         N         0         2         N         N           Indiana         -         1         5         42         204         210         -         1         6         83         28           Indiana         -         3         11         120         136         -         1         5         48         58         66         58         60         1         0         3         46         58         60         1         107         68         107         107         68         108         108         10         10         10         10         10         10         10         10         10         10	Rhode Island§	_	0	2	9	21		0		_				
New Jork (Upstele)         -         3         6         104         154         -         1         4         31         47           New York (Upstele)         3         7         25         261         2265         -         2         17         85         699           New York (Upstele)         -         4         18         270         1         0         31         65         33           Iminosi         -         3         23         277         1         0         31         65         36           Iminosi         -         3         23         117         104         -         0         13         26         66           Michigan         -         4         11         160         125         -         1         4         30         37           Witscontain         1         2         11         106         125         -         1         4         30         37           Witscontain         -         0         37         319         316         -         0         10         66         9         9         9         10         10         10         10	Vermont§	—	0	3	13	12	—		1	2	—			
New York (Üpstate)         3         7         25         261         265          2         17         85         693           Pennsylvania          6         18         270         277         N         0         2         N         N           Binnos          5         123         207         277         N         0         2         N         N           Binnos          5         123         207         214          1         5         283         633           Michigan          3         13         185         215         1         1         6         53         428         868           Ohio          4         13         185         215         1         1         6         53         428         868         6         6         53         428         53         1         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10	Mid. Atlantic													
New York Chy         -         -         4         12         149         154         1         0         31         65         39           EN. Central         1         1         17         42         735         787         1         6         18         180         226           Indiana         -         3         22         110         100         -         1         5         22         86           Obio         -         3         13         165         11         16         6         180         28         28           Wisconsin         1         2         11         109         122         -         1         4         30         37           Kinnesota         -         0         0         -         -         1         30         73         20         11         107         668           Viscota         -         0         34         146         150         -         0         1         10         653         34           Ibmacota         -         0         33         20         18         -         0         10         10         10 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>														
	New York City		4	12	149	154		0	31	65	39			
Illinois       -       5       12       204       210       -       1       5       23       63         Michigan       -       3       23       117       104       -       0       13       26       26         Michigan       -       3       13       110       20       136       -       1       5       48       88       88         Wincomin       1       2       11       109       22       -       1       1       6       37       37         Wincomin       -       0       37       319       313       -       0       1       N       N       N         Kansas       -       0       34       146       150       -       0       1       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N <td>Pennsylvania</td> <td>_</td> <td></td> <td></td> <td></td> <td>277</td> <td>N</td> <td></td> <td></td> <td>N</td> <td></td>	Pennsylvania	_				277	N			N				
	E.N. Central													
Wiseonsin         1         2         11         109         122          1         4         30         37           WN. Central          0         0           2         11         107         68           Iowa          0         0          0         1         N         N           Minnesota          0         34         146         150          0         14         29         30           Nebrasha          0         1         8         70         74          0         1         29         30           Nebrasha          0         1         2         8         70         74          0         1         2         6         6           South Daviota          0         3         11         1         2         16         6         221         242           District of Columbia         -         0         3         11         12         6         55         6         16         1         1         4         5         16	Michigan	_	3	11	120	136		1	5	48	58			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $														
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		I												
$\begin{array}{c} \mbox{Kanasa} & - & 1 & 5 & 37 & 32 & M & 0 & 1 & N & N \\ \mbox{Minnesola} & - & 0 & 3 & 4 & 46 & 50 & - & 0 & 4 & 29 & 30 \\ \mbox{Missouri} & - & 1 & 3 & 35 & 31 & - & 0 & 4 & 29 & 30 \\ \mbox{Missouri} & - & 0 & 4 & 11 & 8 & - & 0 & 3 & 4 & 6 \\ \mbox{South Dakota} & - & 0 & 4 & 11 & 8 & - & 0 & 3 & 4 & 6 \\ \mbox{South Dakota} & - & 0 & 4 & 11 & 8 & - & 0 & 3 & 4 & 6 \\ \mbox{South Dakota} & - & 0 & 4 & 11 & 8 & - & 0 & 3 & 4 & 6 \\ \mbox{South Dakota} & - & 0 & 1 & 10 & 0 & - & 0 & 0 & - & - \\ \mbox{Delaware} & 0 & 1 & 10 & 0 & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & 1 & 10 & 0 & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & 0 & 1 & 10 & 0 & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & 0 & 1 & 10 & 0 & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & - & 0 & 1 & 10 & 0 & - & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & - & 0 & 1 & 10 & 0 & - & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & - & 0 & 1 & 10 & 0 & - & - & - & 0 & 0 & - & - \\ \mbox{Delaware} & - & 0 & - & 0 & 1 & 10 & 0 & - & - & - & 0 & 0 & - & - & - \\ \mbox{Delaware} & - & 0 & - & 0 & - & 1 & 4 & 51 & - & 0 & 0 & - & - & - \\ \mbox{Delaware} & - & 0 & - & 1 & 5 & 56 & 51 & - & - & 1 & 4 & 51 & 46 \\ \mbox{South Carolina} & - & - & 1 & - & 5 & 56 & 51 & - & - & 0 & 3 & 12 & 6 \\ \mbox{South Carolina} & - & - & 1 & - & 4 & 34 & 33 & - & - & 0 & 3 & 12 & 6 \\ \mbox{South Carolina} & - & - & 1 & - & 4 & 34 & 33 & - & 0 & 0 & N & N \\ \mbox{Missusppi} & N & 0 & 0 & N & N & N & N & 0 & 0 & N & N$		_			319									
$\begin{array}{l l l l l l l l l l l l l l l l l l l $	Kansas	_	1	5				0	1					
Nebraska ⁶ -         1         3         35         31         -         0         1         8         7           South Dakota         -         0         3         20         18          0         3         4         6           South Dakota         -         0         3         20         18          0         2         6         6           Delaware         1         0         3         11         12         N         0         0         N         N           Florida         5         6         12         217         193         3         1         6         52         46           Georgia         1         5         13         208         187         1         2         6         55         65           Maryland ⁶ -         1         4         34         33         -         0         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         N         <		—												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		_												
	North Dakota	_	0	4	11		_	0	3		6			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	South Dakota	—	0	3	20	18	—		2	6	6			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	S. Atlantic										242			
Florida 5 6 6 12 217 193 3 1 6 52 46		1									N			
Maryland ⁶ 2         3         12         140         146          1         4         51         46           North Carolina ⁶ 1         5         56         51         1         1         6         33         42           Wrighia ⁶ 1         4         34         33          0         3         12         6           E.S. Central         1         4         10         148         15         3         2         7         64         63           Alabama ⁵ N         0         0         N         N         0         0         N         N         0         0         N         N           Kentucky          1         5         28         31         N         0         0         N         N           Kentucky          1         3         9         120         114         3         1         6         50         55           WS. Central         4         9         79         324         366         4         6         46         203         191		5	6	12	217	193	3	1	6	52	46			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $														
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		2	2											
West Virginia          1         4         34         33          0         3         12         6           E.S. Central         1         4         10         148         145         3         2         7         64         63           Alabama ⁸ N         0         0         N         N         0         0         N         N           Kentucky          1         5         28         31         N         0         0         N         N           Mississippi         N         0         0         N         N          0         2         14         8           Tennessee ⁵ 1         3         9         120         114         3         1         6         50         55           W.S. Central         4         9         79         324         366         4         6         46         203         192           Arkansas ⁵ -         0         2         11         14         34         126         121           Louisian         -         0         2         38         429         -	South Carolina§	_	1	5	56	51		1		33	42			
E.S. Central       1       4       10       148       145       3       2       7       64       63         Alabama ³ N       0       0       N       N       N       0       0       N       N         Mentucky       —       1       5       28       31       N       0       0       N       N         Mississippi       N       0       0       N       N       —       0       2       14       8         Tennessee ⁹ 1       3       9       120       114       3       1       6       55         WS. Central       4       9       79       324       366       4       6       46       203       192         Arkansas ⁶ —       0       3       11       14       —       0       3       13       11         Oklahoma       —       3       20       108       85       3       1       7       43       49         Texas ⁵ 4       5       59       191       259       1       4       34       126       121         Mountan ⁶ 10       22 </td <td></td> <td>—</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		—												
Alabama [§] N       0       0       N       N       N       0       0       N       N         Mississippi       N       0       0       0       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N       N <td>°</td> <td></td>	°													
Kentucky Mississippi Tennessee 6N00NNN00NNNMississippi 														
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		—	1	5	28			0	0		N			
W.S. Central49793243664646203192Arkansas*02148042111Louisiana031114031311Oklahoma320108853174349Texas*45591912591434126121Mountain61022338429416169194Arizona3371151512108889Colorado339111107143243Idaho*0277339111107143243Idaho*0271202733Montana*N00NNNNNNNNevada*0158013Mortana*0116011Vexico*2759103042338Alaska116031724A														
$\begin{array}{cccccccccccccccccccccccccccccccccccc$														
Louisiana          0         3         11         14          0         3         13         11           Oklahoma          3         20         108         85         3         1         7         43         49           Texas ⁵ 4         5         59         191         259         1         4         34         126         121           Mountain         6         10         22         338         429          4         16         169         194           Arizona         3         3         7         115         151          2         10         88         89           Colorado         3         3         9         111         107          0         2         7         3           Montana [§] N         0         0         N         N         N         0         0         N         N           Nevada [§] 0         1         5         8          0         41         5         27           Utah          1         1         6				79 2										
Texas [§] 4       5       59       191       259       1       4       34       126       121         Mountain       6       10       22       338       429        4       16       169       194         Arizona       3       3       7       115       151        2       10       88       89         Colorado       3       3       9       111       107        1       4       32       43         Idaho [§] 0       2       7       3       9       111       107        1       4       32       43         Idaho [§] 0       2       7       3       3       9       111       107        1       4       32       43         Montana [§] N       0       0       N       N       N       0       0       N       N         Newada [§] 0       1        3       3       3       3       3       3       3       14       10        0       4       23       38	Louisiana	_	0	3	11	14		0	3	13	11			
Mountain         6         10         22         338         429          4         16         169         194           Arizona         3         3         7         115         151          2         10         88         89           Colorado         3         3         9         111         107          1         4         32         43           Idaho ⁵ 0         2         7         12          0         2         7         3           Montana [§] N         0         0         N         N         N         0         0         N         N           New da [§] 0         1         5         8          0         1          3           New Mexico [§] 0         1         15         27         28           Wyoming [§] 0         1         1         6          0         1          1           Alaska          1         3         21         28          0         2														
Colorado         3         3         9         111         107          1         4         32         43           Idaho [§] 0         2         7         12          0         2         7         3           Montana [§] N         0         0         N         N         N         0         0         N         N           Nevada [§] 0         1         5         8          0         1          3           New Mexico [§] 2         7         59         103          0         4         15         27           Utah          1         6         40         42          0         5         27         28           Wyoming [§] 0         1         1         6          0         1          1           Pacific         3         3         9         114         110          0         3         17         24           California         N         0         0         N <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td><td></td></t<>							1							
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$				22			_							
Montana [§] N         0         0         N         N         N         0         0         N         N           Nevada [§] 0         1         5         8          0         1          3           New Mexico [§] 2         7         59         103          0         4         15         27         28           Wyoming [§] 0         1         6         40         42          0         4         23         38           Alaska          1         3         21         28          0         3         17         24           California         N         0         0         N         N         0         0         N         N           Galifornia         3         3         8         93         82          0         2         6         14           Oregon [§] N         0         0         N         N         N         N         N         N         N           American Samoa          -         -							—							
Nevada [§] 0         1         5         8          0         1          3           New Mexico [§] 2         7         59         103          0         4         15         27         28           Utah          0         1         6         40         42          0         5         27         28           Wyoming [§] 0         1         1         6          0         1          1           Pacific         3         3         9         114         110          0         4         23         38           Alaska          1         3         21         28          0         3         17         24           California         N         0         0         N         N         N         0         0         N         N           Oregon [§] N         0         0         N         N         N         0         0         N         N           Washington         N         0         0<		N					N			7 N				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$														
Wyoming [§] 0         1         1         6          0         1          1           Pacific         3         3         9         114         110          0         4         23         38           Alaska          1         3         21         28          0         3         17         24           California         N         0         0         N         N         N         0         0         N         N           Hawaii         3         3         8         93         82          0         2         6         14           Oregon [§] N         0         0         N         N         N         0         0         N         N           Washington         N         0         0         N         N         N         0         0         N         N           American Samoa          -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -	New Mexico [§]	_												
Pacific         3         3         9         114         110         —         0         4         23         38           Alaska         —         1         3         21         28         —         0         3         17         24           California         N         0         0         N         N         N         0         0         N         N           Hawaii         3         3         8         93         82         —         0         2         6         14           Oregon§         N         0         0         N         N         N         0         0         N         N           Washington         N         0         0         N         N         N         0         0         N         N           American Samoa         —         0         0         —         30         N         0         0         N         N           Guam         —         0         0         —         —         —         0         0         —         —           Puerto Rico         N         0         0         N         N         N <td></td> <td>—</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		—												
Alaska        1       3       21       28        0       3       17       24         California       N       0       0       N       N       N       0       0       N       N         Hawaii       3       3       8       93       82        0       2       6       14         Oregon§       N       0       0       N       N       N       0       0       N       N         Washington       N       0       0       N       N       N       0       0       N       N         American Samoa        0       0	, 0						—							
California         N         0         0         N         N         N         0         0         N         N           Hawaii         3         3         8         93         82          0         2         6         14           Oregon [§] N         0         0         N         N         N         0         0         N         N           Washington         N         0         0         N         N         N         0         0         N         N           American Samoa            30         N         0         0         N         N           Guam          0         0           0         0             Puerto Rico         N         0         0         N         N         N         N         N					21	28	_			23 17	24			
Oregon [§] N         0         0         N         N         N         0         0         N         N           Washington         N         0         0         N         N         N         0         0         N         N           American Samoa          0         0          30         N         0         0         N         N           C.N.M.I.	California			0	N	N		0	0	N	N			
Washington         N         0         0         N         N         N         0         0         N         N           American Samoa          0         0          30         N         0         0         N         N           C.N.M.I.														
American Samoa          0         0          30         N         0         0         N         N           C.N.M.I.														
C.N.M.I.                                                                                                                               _														
Puerto Rico N 0 0 N N N 0 0 N N	C.N.M.I.	—	_	_	—	—	_		_	_	—			
	U.S. Virgin Islands	IN	0	0	IN	IN	N	0	0	N	N			

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

 U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2008 and 2009 are provisional.
 * Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available. (NNDSS event code 11717). § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

## **MMWR**

(36th week)*		Si	treptococ	cus pneur	noniae. in	vasive dis	ease. dru	a resistan								
			All ages				-	jed <5 yea			Syphilis, primary and secondary					
		Prev						vious				Prev	vious			
Reporting area	Current week	52 w	еекs Max	Cum 2009	Cum 2008	Current week	Med	eeks Max	Cum 2009	Cum 2008	Current week	Med	eeks Max	Cum 2009	Cum 2008	
United States	11	60	276	2,007	2,230	3	9	21	312	341	80	262	452	8,929	8,767	
New England	_	1	48	35	46	—	0	5 5	3	7	3	5 1	15	228	218	
Connecticut Maine [§]	_	0	48 2	9	15	_	Ō	1	1	1	1	Ó	5 1	42 1	21 9	
Massachusetts New Hampshire	_	0 0	1 3	3 5	_	_	0 0	1 0	_2	_		4 0	11 2	161 12	155 13	
Rhode Island [§] Vermont [§]	_	0 0	6 2	7 11	18 13	_	0 0	1 0	_	4 2	_	0 0	5 2	12	14 6	
Mid. Atlantic	_	3	14	117	230	_	0	3	20	20	21	35	51	1,278	1,155	
New Jersey New York (Upstate)	_	0 1	0 10	52	48	_	0 0	0 2	10	6	2 1	4 2	13 8	157 86	152 93	
New York City Pennsylvania	_	0 1	4 8	3 62	93 89	_	0	2 2	10	1 13	16 2	23 6	40 12	802 233	721 189	
E.N. Central	1	11	41	450	476		1	7	64	64	15	23	44	730	800	
Illinois Indiana		0 3	0 32	N 161	N 163	<u>N</u>	0 0	0 6	N 22	N 20	5	7 2	19 10	203 115	322 98	
Michigan Ohio	1	0 7	2 18	19 270	17 296	_	0 1	1 4	2 40	2 42	10	3 6	18 17	175 206	129 212	
Wisconsin	—	0	0	_	—	—	0	0	—	—	_	1	4	31	39	
W.N. Central lowa	_	2 0	161 0	94	157	_	0 0	3 0	20	32	3 1	6 0	11 2	214 17	294 14	
Kansas Minnesota	_	1 0	5 156	39	59 23	_	0	2 3	13	4 23	_2	0 1	3 6	22 40	24 73	
Missouri Nebraska [§]	_	1 0	5 0	43	67	_	0	1 0	5	2	_	3 0	7 3	117 14	173 10	
North Dakota South Dakota	—	0 0	3	10	2	_	0	0	_	_	_	0	1	3	_	
South Dakota S. Atlantic	10	26	2 53	2 956	6 913	3	0 4	2 14	2 143	3 149	24	0 64	1 262	1 2,227	 1,931	
Delaware District of Columbia	N	0 0	2 0	15 N	3 N	N	0 0	0 0	N	N	1 3	0 3	3 9	23 120	10 94	
Florida	9 1	15 8	36 25	559 291	521 303	3	2 1	13 5	89 47	97 44		20 14	31 227	672 522	717	
Georgia Maryland [§]	_	0	1	4	4	_	Ó	0	—	1	5	6	16	216	437 236	
North Carolina South Carolina§		0 0	0 0	<u>N</u>	N	<u>N</u>	0 0	0 0		<u>N</u>	4	9 2	21 6	365 81	188 58	
Virginia [§] West Virginia	N	0 2	0 13	N 87	N 82	N	0 0	0 3	N 7	N 7	8	6 0	15 2	224 4	183 8	
E.S. Central		5	25	196	237		1	3	29	43	11	22	36	785	746	
Alabama [§] Kentucky	<u>N</u>	0 1	0 5	N 55	N 58	<u>N</u>	0 0	0 2	N 7	N 9	1	8 1	17 10	288 47	310 60	
Mississippi Tennessee§	_	0 3	3 23	3 138	28 151	_	0 0	1 3	2 20	8 26	6 4	4 8	18 19	158 292	103 273	
W.S. Central	—	1	6	72	76	—	0	3	14	12	—	49	80	1,641	1,480	
Arkansas [§] Louisiana	_	1	5 5	40 32	13 63		0	3 1	9 5	3 9	_	4 11	35 40	151 303	112 403	
Oklahoma Texas§		0 0	0 0		<u>N</u>	<u>N</u>	0 0	0 0		<u>N</u>	_	1 32	7 48	43 1,144	53 912	
<b>Mountain</b> Arizona	_	2 0	7 0	84	93	_	0 0	3 0	17	12	1	9 4	18 9	298 132	443 226	
Colorado	_	0	0	_	_	_	0	0	_	_	_	1	4	61	108	
Idaho [§] Montana [§]	N	0	1	N		<u>N</u>	0	1 0		<u>N</u>		0	2 7	3	2	
Nevada [§] New Mexico [§]	_	1 0	4 0	33	44	_	0 0	2 0	7	5	1	1 1	7 5	66 34	58 30	
Utah Wyoming [§]	_	1 0	6 2	42 9	48 1	_	0 0	3 1	9 1	7	_	0 0	2 1	2	16 3	
Pacific	_	0	1	3	2	_	0	1	2	2	2	44	66	1,528	1,700	
Alaska California	N	0 0	0 0	N	N	N	0 0	0 0	N	N	1	0 39	0 59	1,392	1 1,536	
Hawaii Oregon§	N	0 0	1 0	3 N	2 N	N	0 0	1 0	2 N	2 N	_	0 1	3 4	20 32	16 13	
Washington	Ν	0	0	Ν	Ν	Ν	0	0	Ν	Ν	1	2	7	84	134	
American Samoa C.N.M.I.	<u>N</u>	0		<u>N</u>	<u>N</u>	<u>N</u>	0	0		<u>N</u>	_	0	0	_	_	
Guam Puerto Rico	_	0 0	0 0	_	_	_	0 0	0 0	_	_	_	0 3	0 16	142	101	
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_	—	0	0			

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2008 and 2009 are provisional.
 † Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).
 § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	(36th week)^						West Nile virus disease [†]										
Current         52 weeks         Current         53 weeks         54 weeks         <			Varic	ella (chick	enpox)			N	euroinvasi	ve		Nonneuroinvasive§					
Papeding area         week         Med         Max         2009         2008         week         Med         Max         2009         2008           Linetd State         -         1         1.03         1.232         20.816         1         1         7.7         480         -         1         3.7         1.42         5.38           Maine ¹ -         0         1.1         5.177         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         -         0         0         -         - <td< th=""><th></th><th></th><th></th><th></th><th></th><th>-</th><th></th><th></th><th></th><th>-</th><th></th><th></th><th></th><th></th><th></th><th></th></td<>						-				-							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Reporting area		-														
	United States	74	451	1,035	12,328	20,816	1	1	70	137	480		1	37	142	538	
									2			_			_	3	
	Maine [¶]	_	0	11				0	0	_	_		0	0	_	_	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						186			-					-			
Mid. Atlantic         10         39         58         1068         1.658         -         0         6         2         31         -         0         2         -         15           New York (Upstate)         N         0         0         N         N         -         0         2         -         1         1         1         0         2         -         4           New York (Upstate)         N         0         0         N         N         -         0         2         1         1         2         0         0         -         4           New York (Upstate)         20         155         254         4.282         5.038         -         0         7         1         2         0         1         -         -         0         1         -         -         0         1         -         -         0         1         1         2         -         0         1         -         -         -         0         1         -         -         0         1         -         2         -         0         1         -         2         1         1         0         2		—				—									—		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		10													_		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$										_					_	4	
	New York City	_	0	0	_	_		0	2	_	6		0	1	_	5	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					,	,								-			
	Illinois		35	73	904			0	4	1	4		0				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						2 105	_			1		_		1	_		
	Ohio	13	42	91	1,455	1,611	_	0	3		8	_	0	1		_	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	lowa		0	0	N	N	—	0	1	—	2		0	1	2	2	
		_			176	323											
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Missouri		10	51			_	0	3		5	_	0	•	_	2	
Delaware         -         0         4         8         130         -         0         0         -         -         -         0         0         -         1         -         1         2           Florida         11         28         67         938         1,195         -         0         0         -         3         -         0         0         -         -         -         -         0         0         -         -         -         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         0         0         -         -         0         0         -         1         1         0         0         -         1         1         1         0         0         -         1         1         1         1         1         1         1         1         0         0         -         1         1         1         1         1         1         1         1         1         1         1         1         1         1 <td></td> <td>—</td> <td></td> <td></td> <td>9</td> <td></td>												—			9		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $															_		
														•	—		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$							_								_	4	
															_		
West Virginia         6         9         32         314         519         -         0         0         -         1         -         0         5         23         37         -         0         5         13         50           Alabama ¹ -         11         28         356         869         -         0         1         -         10         -         0         2         -         5           Kentucky         N         0         0         N         N         -         0         1         1         -         0         0         -         -         -         5         21         18         -         0         3         12         38           Tennessee ¹ N         0         0         N         N         -         0         2         1         9         -         0         1         1         6         -         0         1         1         6         7         7         6         495         -         0         1         1         1         0         1         1         7         6         5         1         3         1         0 <td>South Carolina[¶]</td> <td></td> <td>3</td> <td>54</td> <td>154</td> <td>602</td> <td></td> <td>0</td> <td>1</td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>_</td> <td>1</td>	South Carolina [¶]		3	54	154	602		0	1				0	0	_	1	
E.S. Contral       -       11       28       358       879       -       0       5       23       37       -       0       5       13       50         Alabama ¹ -       11       28       356       869       -       0       1       -       10       -       0       2       -       5         Mississippi       -       0       1       1       -       -       0       3       12       38         Tennessee ¹ N       0       0       N       N       -       0       2       1       9       -       0       1       1       -       -       0       3       12       38         Tennessee ¹ -       94       747       3,259       6,243       -       0       8       41       55       -       0       5       61       45         Arkansa ¹ -       3       47       7       76       57       -       0       3       40       -       0       7       30       34       -       0       10       20         Mountain       20       33       83       957 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>_</td><td></td><td></td><td></td><td></td><td>_</td><td>1</td></td<>										_					_	1	
Kentucky       N       0       0       N       N       N       -       0       1       1       -       -       0       0       -       -       -       0       1       1       -       -       0       3       12       38         Tennessee"       N       0       0       N       N       -       0       5       21       18       -       0       3       12       38         Tennessee"       N       0       0       N       N       -       0       8       41       55       -       0       5       16       45         Arkansas"       -       3       47       96       495       -       0       1       1       6       -       0       5       6       18         Oklahoma       N       0       0       N       -       0       7       30       34       -       0       3       10       20         Texas"       -       8       39       68       -       0       11       37       -       0       11       38       51         Idaho"       N       0       0	E.S. Central		11	28	358	879		0	5	23	37		0	5	13		
Mississippi        0       1       2       10        0       5       21       18        0       3       12       38         Tennessee"       N       0       0       N       N        0       2       1       9        0       1       1       7         W.S. Central        3       47       3,59       6,243        0       1       1       6        0       0        2       1       7       7         W.S. Central        3       47       96       495        0       1       1       6        0       0        2       1       14       2        0       6       13       13        0       3       10       20       0        5       5       11       37        0       3       10       20       10       20       11       37        0       15       60       148       42       27       10       13       13        0       11       38       51 </td <td></td> <td>N</td> <td></td> <td></td> <td></td> <td></td> <td>_</td> <td></td> <td></td> <td></td> <td></td> <td>_</td> <td></td> <td></td> <td>_</td> <td></td>		N					_					_			_		
W.S. Central       -       94       747       3,259       6,243       -       0       8       41       55       -       0       5       16       45         Arkansas ¹ -       3       47       96       495       -       0       1       1       6       -       0       5       16       45         Louisiana       -       1       7       76       57       -       0       1       4       2       -       0       0       -       5       6       18         Oklahoma       N       0       0       N       N       -       0       1       4       2       -       0       0       -       5       6       18         Mountain       20       33       83       957       1,524       -       0       8       39       68       -       0       11       37       -       0       8       427         Colorado       20       12       24       38       622       -       0       1       2       3       -       0       1       1       35         Idaho ¹¹ N       0	Mississippi	—	0	1	2	10		0	5	21	18		0	3		38	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		N															
Oklahoma         N         0         0         N         N         -         0         1         4         2         -         0         0         -         5           Texas ^{II} -         0         3         3087         5,691         -         0         7         30         34         -         0         3         10         20           Mountain         20         33         83         957         1,524         -         0         8         39         68         -         0         11         38         4         27           Colorado         20         12         44         388         622         -         0         4         13         13         -         0         11         38         51           Idaho ^{II} N         0         0         N         N         -         0         1         2         3         -         0         11         15         60           Idaho ^{III} N         0         0         N         N         -         0         1         2         4         -         0         1         1         1 <th< td=""><td>Arkansas[¶]</td><td>_</td><td>3</td><td>47</td><td>96</td><td>495</td><td>_</td><td>0</td><td>1</td><td>1</td><td>6</td><td>_</td><td>0</td><td>0</td><td>_</td><td>2</td></th<>	Arkansas [¶]	_	3	47	96	495	_	0	1	1	6	_	0	0	_	2	
Texas [¶] -       86       721       3,087       5,691       -       0       7       30       34       -       0       3       10       20         Mountain       20       33       83       957       1,524       -       0       8       39       68       -       0       15       60       148         Arizona       -       0       13       13       -       0       11       37       -       0       8       4       27         Colorado       20       12       44       388       622       -       0       4       13       13       -       0       11       38       51         Idaho [¶] N       0       0       N       N       -       0       1       2       3       -       0       1       10       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1       1 <td></td>																	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Texas [¶]				,	,	—		-		34	—					
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		20				1,524											
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Colorado		12	44				0		13	13	—	0	11	38	51	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			2	-			_		1	2	_	_	0	2	6 1		
Utah        13       31       330       496        0       1        4        0       1        18         Wyoming ^{III} 0       1        10        0       1       2         0       1        18         Pacific        2       7       80       92       1       0       34       19       213        0       0         0       0         0       0       2       5       8         Alaska        1       6       50       44        0       0         0       0       25       133         Alaska        1       6       50       44        0       0         0       0          0       0          0       0       0          0       0         10       0       0        13       33	Nevada [¶]	Ν	0				_			7		—		1			
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Utah	_	13			496	_	0		_	-	_	0	1	_	18	
Alaska        1       6       50       44        0       0          0       0         California         Hawaii        0       0         1       0       33       16       209        0       0       18       119         Hawaii        1       4       30       48        0       0         0       0         0       0         0       0         0       0         0       0         0       0          0       0         0       0          0       0         0       0         13       Washington       N       0       0       N       N        0       0         113       Maxington       N       N       N       N       0       0         0       0												—					
Hawaii        1       4       30       48        0       0         0       0         0       0         0       0         0       0          0       0         0       0         0       0        13         Washington       N       0       0       N       N        0       2       3       2        0       3       7       1         American Samoa       N       0       0       N       N        0       0         0       0          0       0          0       0          0       0          0       0          0       0          0       0          0       0          0       0	Alaska	_	1	6			—	0	0	_	_	_	0	0	_	_	
Oregon [¶] N         0         0         N         N         -         0         1         -         2         -         0         0         -         13           Washington         N         0         0         N         N         -         0         2         3         2         -         0         3         7         1           American Samoa         N         0         0         N         N         -         0         0         -         -         -         0         0         -         1         -         2         3         2         -         0         3         7         1           American Samoa         N         0         0         N         N         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         -         0         0         -         -         -         -         0         0 </td <td></td> <td>_</td> <td></td> <td>-</td> <td></td> <td></td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td>_</td> <td></td> <td></td> <td>18</td> <td></td>		_		-			1					_			18		
American Samoa         N         0         0         N         N          0         0            0         0            0         0            0         0            0         0            0         0             0         0            0         0            0         0             0         0            0         0            0         0            0         0            0         0            0         0           0         0            0         0           0         0           0         0           0         0	Oregon [¶]		Ó	0	N	N	_	0	1	_	2	_	0	Ō		13	
C.N.M.I.				-						3	2	—			7	1	
Puerto Rico – 8 23 318 442 – 0 0 – – 0 0 – –	C.N.M.I.		_	_	_	—	_	_	_	_	_		_	_	_	_	
		_					_			_	_	_			_	_	
		_					_			_	_	_			_	_	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending September 12, 2009, and September 6, 2008 (36th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance).

Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

[§] Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

## TABLE III. Deaths in 122 U.S. cities,* week ending September 12, 2009 (36th week)

All causes, by age (years)								All cau	uses, by	age (yea	rs)				
Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I [†] Total	Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I [†] Total
New England	458	304	94	33	15	12	44	S. Atlantic	1,077	656	295	72	25	29	38
Boston, MA	118	68	29	10	6	5	6	Atlanta, GA	109	67	25	9	3	5	4
Bridgeport, CT	15	12	3		—	—		Baltimore, MD	145	86	43	11	2	3	12
Cambridge, MA	13	11	1	1	_	—	1	Charlotte, NC	86	53	26	4	3	_	1
Fall River, MA	14 30	9	2	2 2	1 1	1	2	Jacksonville, FL	150 82	87 53	49	8	3	3 3	1
Hartford, CT Lowell, MA	30	18 25	8 3	∠ 3	I	_	1 1	Miami, FL Norfolk, VA	82 29	53 18	18 8	5 3	3	3	2 2
Lvnn. MA	10	10			_	_	_	Richmond, VA	43	23	15	2	2	1	
New Bedford, MA	27	19	4	4	_	_	3	Savannah, GA	38	20	10	2		6	1
New Haven, CT	22	15	7	_	_	_	4	St. Petersburg, FL	48	34	9	3	2	_	3
Providence, RI	62	37	14	6	5	_	8	Tampa, FL	159	107	36	9	3	4	7
Somerville, MA	1	_	1	_	_		_	Washington, D.C.	183	105	54	16	4	4	5
Springfield, MA	30	18	7	2	1	2	6	Wilmington, DE	5	3	2	_	_	_	_
Waterbury, CT	15	13	1	1	_	_	2	E.S. Central	756	486	183	44	28	15	54
Worcester, MA	70	49	14	2	1	4	10	Birmingham, AL	173	115	34	8	8	8	10
Mid. Atlantic	1,678	1,156	363	94	38	27	73	Chattanooga, TN	52	38	9	1	3	1	4
Albany, NY	50	36	6	3	1	4	2	Knoxville, TN	95	61	24	3	7	—	6
Allentown, PA	23	20	2	—	1	—	_	Lexington, KY	62	44	10	6	1	1	4
Buffalo, NY	81	59	16	3	3	_	3	Memphis, TN	139	83	39	10	6	1	10
Camden, NJ	39	20	11	2	1	5	_	Mobile, AL	60	38	19	1	1	1	_
Elizabeth, NJ	10	6	2	2	_	_	_	Montgomery, AL	58	35	17	5	1	_	5
Erie, PA	49	31	13	1	2	2	4	Nashville, TN	117	72	31	10	1	3	15
Jersey City, NJ	32	19	9	2	1	1	4	W.S. Central	968	579	260	74	30	25	53
New York City, NY	881	617	191	53	15	5	33	Austin, TX	69	43	16	7	2	1	2
Newark, NJ	32 8	16 7	9 1	3	1	3	5	Baton Rouge, LA	58 U	51 U	5 U	2 U	U	U	 U
Paterson, NJ Philadelphia, PA	8 228	132	64	18	8	6	9	Corpus Christi, TX Dallas, TX	182	100	47	16	7	12	11
Pittsburgh, PA§	220 U	132 U	04 U	U	Ů	U	U	El Paso, TX	57	36	47	4	2		2
Reading, PA	26	23	2	1	_	_	1	Fort Worth, TX	U 37	- 30 U	U	Ŭ	Ű	U	Ű
Rochester, NY	113	92	14	2	4	1	4	Houston, TX	295	161	91	23	9	11	13
Schenectady, NY	22	18	4		_	_	3	Little Rock, AR	U	Ŭ	Ŭ	Ū	Ŭ	Ü	Ŭ
Scranton, PA	26	20	4	2	_	_	2	New Orleans, LA	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ
Syracuse, NY	6	4	2	_	_		1	San Antonio, TX	182	112	50	14	6	_	17
Trenton, NJ	22	15	6	1	_	_	_	Shreveport, LA	39	22	14	2	1	_	2
Utica, NY	12	9	2	_	1	_	1	Tulsa, OK	86	54	22	6	3	1	6
Yonkers, NY	18	12	5	1	_	_	1	Mountain	991	642	255	59	15	19	47
E.N. Central	1,387	901	347	81	33	25	76	Albuquerque, NM	103	75	20	7	_	1	6
Akron, OH	40	25	9	2	2	2	1	Boise, ID	59	43	13	2	—	1	3
Canton, OH	39	26	11	1	_	1	5	Colorado Springs, CO	94	62	27	4	1	—	4
Chicago, IL	U	U	U	U	U	U	U	Denver, CO	82	41	23	10	2	5	4
Cincinnati, OH	63	31	18	3	10	1	5	Las Vegas, NV	220	139	64	11	3	3	10
Cleveland, OH	192	123	44	19	4	2	4	Ogden, UT	32	27	2	3	_	_	2
Columbus, OH	224	145	59	17	2	1	17	Phoenix, AZ	145	78	49	8	5	5	7
Dayton, OH	98	65	27	3	1	2	6	Pueblo, CO	20	16	4	_	2	_	1
Detroit, MI Evansville, IN	104 43	54 29	35 13	11 1	3	1	4 6	Salt Lake City, UT Tucson, AZ	116 120	76 85	27 26	9 5	2	2 2	3 7
Fort Wayne, IN	43 52	29 36	13	1	1	1	1	Pacific	1,243	820	292	80	33	18	117
Gary, IN	10	4	5	_	_	1	_	Berkeley, CA	1,243	7	4	1			2
Grand Rapids, MI	40	29	6	2	1	2	4	Fresno, CA	Ű	Ú	Ū	Ů	U	U	Ű
Indianapolis, IN	150	91	45	7	3	4	6	Glendale, CA	31	27	3	_	1	_	8
Lansing, MI	44	32	.0	2	2		1	Honolulu, HI	70	54	11	2	3	_	6
Milwaukee, WI	45	32	11	1	_	1	5	Long Beach, CA	63	49	8	4	2	_	10
Peoria, IL	35	20	12	_	1	2	2	Los Angeles, CA	216	130	50	21	9	6	25
Rockford, IL	47	29	11	5	2	_	2	Pasadena, CA	17	11	3	2	_	1	1
South Bend, IN	37	30	4	_	_	3	3	Portland, OR	99	66	28	2	2	1	4
Toledo, OH	79	67	8	2	1	1	4	Sacramento, CA	149	95	35	12	4	3	12
Youngstown, OH	45	33	8	4	_	—	_	San Diego, CA	45	25	11	5	4	—	5
W.N. Central	541	330	132	48	9	21	39	San Francisco, CA	93	65	20	7	_	1	12
Des Moines, IA	80	49	22	6	1	2	4	San Jose, CA	163	113	40	8	2	_	18
Duluth, MN	24	19	3	2	—	—	3	Santa Cruz, CA	27	18	8		1		2
Kansas City, KS	15	4	8	3	_	—	1	Seattle, WA	114	67	35	6	3	3	8
Kansas City, MO	64	35	23	6	_	—	4	Spokane, WA	50	26	18	3	1	2	
Lincoln, NE	29	24	4	1	_	_	5	Tacoma, WA	94	67	18	7	1	1	4
Minneapolis, MN	62	35	17	3	3	4	4	Total ¹	9,099	5,874	2,221	585	226	191	541
Omaha, NE	77	55	13	5	1	3	6								
St. Louis, MO	63	27	13	10	2	10	6	1							
St. Paul, MN	67	51	8	7		1	3	1							
Wichita, KS	60	31	21	5	2	1	3	1							

U: Unavailable. —:No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. * Pneumonia and influenza.

⁵ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹ Total includes unknown ages.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR*'s free subscription page at *http://www.cdc.gov/mmwr/mmwrsubscribe.html*. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆ U.S. Government Printing Office: 2009-523-019/41199 Region IV ISSN: 0149-2195